{"id":"pegfilgrastim","rwe":[],"_fda":{"id":"1043b30b-ea11-4192-8871-cea86bc8529c","set_id":"7dada041-6528-4acf-809c-62d271538c9a","openfda":{"nui":["M0024696","N0000009451","N0000175666"],"unii":["3A58010674"],"route":["SUBCUTANEOUS"],"rxcui":["2260704","2260709"],"spl_id":["1043b30b-ea11-4192-8871-cea86bc8529c"],"brand_name":["ZIEXTENZO"],"spl_set_id":["7dada041-6528-4acf-809c-62d271538c9a"],"package_ndc":["61314-866-01","61314-866-02"],"product_ndc":["61314-866"],"generic_name":["PEGFILGRASTIM-BMEZ"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Granulocyte Colony-Stimulating Factor [CS]"],"pharm_class_pe":["Increased Myeloid Cell Production [PE]"],"substance_name":["PEGFILGRASTIM"],"pharm_class_epc":["Leukocyte Growth Factor [EPC]"],"manufacturer_name":["Sandoz Inc"],"application_number":["BLA761045"],"is_original_packager":[true]},"version":"20","pregnancy":["8.1 Pregnancy Risk Summary Although available data with ZIEXTENZO or pegfilgrastim product use in pregnant women are insufficient to establish whether there is a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes, there are available data from published studies in pregnant women exposed to filgrastim products. These studies have not established an association of filgrastim product use during pregnancy with major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal studies, no evidence of reproductive/developmental toxicity occurred in the offspring of pregnant rats that received cumulative doses of pegfilgrastim approximately 10 times the recommended human dose (based on body surface area). In pregnant rabbits, increased embryolethality and spontaneous abortions occurred at 4 times the maximum recommended human dose simultaneously with signs of maternal toxicity (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data Pregnant rabbits were dosed with pegfilgrastim subcutaneously every other day during the period of organogenesis. At cumulative doses ranging from the approximate human dose to approximately 4 times the recommended human dose (based on body surface area), the treated rabbits exhibited decreased maternal food consumption, maternal weight loss, as well as reduced fetal body weights and delayed ossification of the fetal skull; however, no structural anomalies were observed in the offspring from either study. Increased incidences of post-implantation losses and spontaneous abortions (more than half the pregnancies) were observed at cumulative doses approximately 4 times the recommended human dose, which were not seen when pregnant rabbits were exposed to the recommended human dose. Three studies were conducted in pregnant rats dosed with pegfilgrastim at cumulative doses up to approximately 10 times the recommended human dose at the following stages of gestation: during the period of organogenesis, from mating through the first half of pregnancy, and from the first trimester through delivery and lactation. No evidence of fetal loss or structural malformations was observed in any study. Cumulative doses equivalent to approximately 3 and 10 times the recommended human dose resulted in transient evidence of wavy ribs in fetuses of treated mothers (detected at the end of gestation but no longer present in pups evaluated at the end of lactation)."],"overdosage":["10 OVERDOSAGE Overdosage of pegfilgrastim products may result in leukocytosis and bone pain. Events of edema, dyspnea, and pleural effusion have been reported in a single patient who administered pegfilgrastim on 8 consecutive days in error. In the event of overdose, the patient should be monitored for adverse reactions [see Adverse Reactions ( 6 )]."],"description":["11 DESCRIPTION Pegfilgrastim-bmez is a covalent conjugate of recombinant methionyl human G-CSF and monomethoxypolyethylene glycol. Recombinant methionyl human G-CSF is a water-soluble 175 amino acid protein with a molecular weight of approximately 19 kilodaltons (kD). Recombinant methionyl human G-CSF is obtained from the bacterial fermentation of a strain of E coli transformed with a genetically engineered plasmid containing the human G-CSF gene. To produce pegfilgrastim-bmez, a 20 kD monomethoxypolyethylene glycol molecule is covalently bound to the N-terminal methionyl residue of recombinant methionyl human G-CSF. The average molecular weight of pegfilgrastim-bmez is approximately 39 kD. ZIEXTENZO for manual subcutaneous injection is supplied in 0.6 mL prefilled syringes. The prefilled syringe does not bear graduation marks and is designed to deliver the entire contents of the syringe (6 mg/0.6 mL). The delivered 0.6 mL dose from the prefilled syringe for manual subcutaneous injection contains 6 mg pegfilgrastim-bmez (based on protein weight) in a sterile, clear, colorless to slightly yellowish, preservative-free solution (pH 4.0, sodium hydroxide may be added as necessary to adjust pH) containing acetic acid (0.36 mg), polysorbate 20 (0.02 mg), sorbitol (30 mg), and Water for Injection, USP."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING ZIEXTENZO single-dose prefilled syringe for manual use ZIEXTENZO injection is a clear, colorless to slightly yellowish solution supplied in a prefilled single-dose syringe for manual use containing 6 mg pegfilgrastim-bmez, supplied with a 29-gauge, 1/2-inch needle with an UltraSafe Passive TM Needle Guard. The ZIEXTENZO syringe plunger stopper and needle cap are not made with natural rubber latex. ZIEXTENZO is provided in a dispensing pack containing one sterile 6 mg/0.6 mL prefilled syringe (NDC 61314-866-02). ZIEXTENZO prefilled syringe does not bear graduation marks and is intended only to deliver the entire contents of the syringe (6 mg/0.6 mL) for direct administration. Use of the prefilled syringe is not recommended for direct administration for pediatric patients weighing less than 45 kg who require doses that are less than the full contents of the syringe. Store refrigerated between 36°F to 46°F (2°C to 8°C) in the carton to protect from light. Do not shake. Discard syringes stored at room temperature for more than 120 hours. Avoid freezing; if frozen, thaw in the refrigerator before administration. Discard syringe if frozen more than once."],"geriatric_use":["8.5 Geriatric Use Of the 932 patients with cancer who received pegfilgrastim in clinical studies, 139 (15%) were aged 65 and over, and 18 (2%) were aged 75 and over. No overall differences in safety or effectiveness were observed between patients aged 65 and older and younger patients."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of ZIEXTENZO have been established in pediatric patients. No overall differences in safety were identified between adult and pediatric patients based on postmarketing surveillance and review of the scientific literature. Use of ZIEXTENZO in pediatric patients for chemotherapy-induced neutropenia is based on ZIEXTENZO’s approval as a biosimilar to pegfilgrastim and evidence from adequate and well-controlled studies of pegfilgrastim in adults with additional pharmacokinetic and safety data of pegfilgrastim in pediatric patients with sarcoma [see Clinical Pharmacology ( 12.3 ) and Clinical Studies ( 14.1 )]. The use of ZIEXTENZO to increase survival in pediatric patients acutely exposed to myelosuppressive doses of radiation is based on ZIEXTENZO’s approval as a biosimilar to pegfilgrastim and evidence from efficacy studies of pegfilgrastim conducted in animals and clinical data supporting the use of pegfilgrastim in patients with cancer receiving myelosuppressive chemotherapy. Efficacy studies of pegfilgrastim products could not be conducted in humans with acute radiation syndrome for ethical and feasibility reasons. Results from population modeling and simulation indicate that two doses of pegfilgrastim (Table 1), administered one week apart provide pediatric patients with exposures comparable to that in adults receiving two 6 mg doses one week apart [see Dosage and Administration ( 2.3 ), Clinical Pharmacology ( 12.3 ) and Clinical Studies ( 14.2 )]."],"effective_time":"20240227","clinical_studies":["14 CLINICAL STUDIES 14.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy Pegfilgrastim was evaluated in three randomized, double-blind, controlled studies. Studies 1 and 2 were active-controlled studies that employed doxorubicin 60 mg/m 2 and docetaxel 75 mg/m 2 administered every 21 days for up to 4 cycles for the treatment of metastatic breast cancer. Study 1 investigated the utility of a fixed dose of pegfilgrastim. Study 2 employed a weight-adjusted dose. In the absence of growth factor support, similar chemotherapy regimens have been reported to result in a 100% incidence of severe neutropenia (ANC < 0.5 x 10 9 /L) with a mean duration of 5 to 7 days and a 30% to 40% incidence of febrile neutropenia. Based on the correlation between the duration of severe neutropenia and the incidence of febrile neutropenia found in studies with filgrastim, duration of severe neutropenia was chosen as the primary endpoint in both studies, and the efficacy of pegfilgrastim was demonstrated by establishing comparability to filgrastim-treated patients in the mean days of severe neutropenia. In Study 1, 157 patients were randomized to receive a single subcutaneous injection of pegfilgrastim (6 mg) on day 2 of each chemotherapy cycle or daily subcutaneous filgrastim (5 mcg/kg/day) beginning on day 2 of each chemotherapy cycle. In Study 2, 310 patients were randomized to receive a single subcutaneous injection of pegfilgrastim (100 mcg/kg) on day 2 or daily subcutaneous filgrastim (5 mcg/kg/day) beginning on day 2 of each chemotherapy cycle. Both studies met the major efficacy outcome measure of demonstrating that the mean days of severe neutropenia of pegfilgrastim-treated patients did not exceed that of filgrastim-treated patients by more than 1 day in cycle 1 of chemotherapy. The mean days of cycle 1 severe neutropenia in Study 1 were 1.8 days in the pegfilgrastim arm compared to 1.6 days in the filgrastim arm [difference in means 0.2 (95% CI -0.2, 0.6)] and in Study 2 were 1.7 days in the pegfilgrastim arm compared to 1.6 days in the filgrastim arm [difference in means 0.1 (95% CI - 0.2, 0.4)]. A secondary endpoint in both studies was days of severe neutropenia in cycles 2 through 4 with results similar to those for cycle 1. Study 3 was a randomized, double-blind, placebo-controlled study that employed docetaxel 100 mg/m 2 administered every 21 days for up to 4 cycles for the treatment of metastatic or non-metastatic breast cancer. In this study, 928 patients were randomized to receive a single subcutaneous injection of pegfilgrastim (6 mg) or placebo on day 2 of each chemotherapy cycle. Study 3 met the major trial outcome measure of demonstrating that the incidence of febrile neutropenia (defined as temperature ≥ 38.2°C and ANC ≤ 0.5 x 10 9 /L) was lower for pegfilgrastim-treated patients as compared to placebo-treated patients (1% versus 17%, respectively, p < 0.001). The incidence of hospitalizations (1% versus 14%) and IV anti-infective use (2% versus 10%) for the treatment of febrile neutropenia was also lower in the pegfilgrastim-treated patients compared to the placebo-treated patients. Study 4 was a multicenter, randomized, open-label study to evaluate the efficacy, safety, and pharmacokinetics [see Clinical Pharmacology ( 12.3 )] of pegfilgrastim in pediatric and young adult patients with sarcoma. Patients with sarcoma receiving chemotherapy age 0 to 21 years were eligible. Patients were randomized to receive subcutaneous pegfilgrastim as a single-dose of 100 mcg/kg (n = 37) or subcutaneous filgrastim at a dose 5 mcg/kg/day (n = 6) following myelosuppressive chemotherapy. Recovery of neutrophil counts was similar in the pegfilgrastim and filgrastim groups. The most common adverse reaction reported was bone pain. 14.2 Patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome Efficacy studies of pegfilgrastim products could not be conducted in humans with acute radiation syndrome for ethical and feasibility reasons. Approval of this indication was based on efficacy studies conducted in animals and data supporting pegfilgrastim’s effect on severe neutropenia in patients with cancer receiving myelosuppressive chemotherapy [see Dosage and Administration ( 2.1 )]. The recommended dose of ZIEXTENZO is two doses, 6 mg each, administered one week apart for humans exposed to myelosuppressive doses of radiation. For pediatric patients weighing less than 45 kg, dosing of ZIEXTENZO is weight based and is provided in Table 1 [see Dosage and Administration ( 2.3 )]. This dosing regimen is based on population modeling and simulation analyses. The exposure associated with this dosing regimen is expected to provide sufficient pharmacodynamic activity to treat humans exposed to myelosuppressive doses of radiation [see Clinical Pharmacology ( 12.3 )]. The safety of pegfilgrastim at a dose of 6 mg has been assessed on the basis of clinical experience in patients with cancer receiving myelosuppressive chemotherapy. The efficacy of pegfilgrastim for the acute radiation syndrome setting was studied in a randomized, placebo-controlled non-human primate model of radiation injury. Rhesus macaques were randomized to either a control (n = 23) or treated (n = 23) cohort. On study day 0, animals (n = 6 to 8 per irradiation day) were exposed to total body irradiation (TBI) of 7.50 ± 0.15 Gy delivered at 0.8 ± 0.03 Gy/min, representing a dose that would be lethal in 50% of animals by 60 days of follow-up (LD50/60). Animals were administered subcutaneous injections of a blinded treatment (control article [5% dextrose in water] or pegfilgrastim [300-319 mcg/kg/day]) on study day 1 and on study day 8. The primary endpoint was survival. Animals received medical management consisting of intravenous fluids, antibiotics, blood transfusions, and other support as required. Pegfilgrastim significantly (at 0.0014 level of significance) increased 60-day survival in irradiated non-human primates: 91% survival (21/23) in the pegfilgrastim group compared to 48% survival (11/23) in the control group."],"pharmacodynamics":["12.2 Pharmacodynamics Animal data and clinical data in humans suggest a correlation between pegfilgrastim products’ exposure and the duration of severe neutropenia as a predictor of efficacy. Selection of the dosing regimen of ZIEXTENZO is based on reducing the duration of severe neutropenia."],"pharmacokinetics":["12.3 Pharmacokinetics The pharmacokinetics of pegfilgrastim was studied in 379 patients with cancer. The pharmacokinetics of pegfilgrastim was nonlinear, and clearance decreased with increases in dose. Neutrophil receptor binding is an important component of the clearance of pegfilgrastim, and serum clearance is directly related to the number of neutrophils. In addition to numbers of neutrophils, body weight appeared to be a factor. Patients with higher body weights experienced higher systemic exposure to pegfilgrastim after receiving a dose normalized for body weight. A large variability in the pharmacokinetics of pegfilgrastim was observed. The half-life of pegfilgrastim ranged from 15 to 80 hours after subcutaneous injection. Specific Populations No gender-related differences were observed in the pharmacokinetics of pegfilgrastim, and no differences were observed in the pharmacokinetics of geriatric patients (≥ 65 years of age) compared with younger patients (< 65 years of age) [see Use in Specific Populations ( 8.5 )]. Renal Impairment In a study of 30 subjects with varying degrees of renal dysfunction, including end stage renal disease, renal dysfunction had no effect on the pharmacokinetics of pegfilgrastim. Pediatric Patients with Cancer Receiving Myelosuppressive Chemotherapy The pharmacokinetics and safety of pegfilgrastim were studied in 37 pediatric patients with sarcoma in Study 4 [see Clinical Studies 14.1 ] . The mean (± standard deviation [SD]) systemic exposure (AUC 0-inf ) of pegfilgrastim after subcutaneous administration at 100 mcg/kg was 47.9 (± 22.5) mcg·hr/mL in the youngest age group (0 to 5 years, n = 11), 22.0 (± 13.1) mcg·hr/mL in the 6 to 11 years age group (n = 10), and 29.3 (± 23.2) mcg·hr/mL in the 12 to 21 years age group (n = 13). The terminal elimination half-lives of the corresponding age groups were 30.1 (± 38.2) hours, 20.2 (± 11.3) hours, and 21.2 (± 16.0) hours, respectively. Patients Acutely Exposed to Myelosuppressive Doses of Radiation The pharmacokinetics of pegfilgrastim products is not available in patients acutely exposed to myelosuppressive doses of radiation. Based on limited pharmacokinetic data in irradiated non-human primates, the area under the concentration-time curve (AUC), reflecting the exposure to pegfilgrastim in non-human primates following a 300 mcg/kg dose of pegfilgrastim, appears to be greater than in humans receiving a 6 mg dose. Results from population modeling and simulation indicate that two 6 mg doses of pegfilgrastim administered one week apart in adults result in clinically relevant effects on duration of grade 3 and 4 neutropenia. In addition, weight based dosing in pediatric patients weighing less than 45 kg [ see Dosage and Administration, Section 2.3 , Table 1 ] provides exposures comparable to those in adults receiving two 6 mg doses one week apart."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: • Splenic Rupture [see Warnings and Precautions ( 5.1 )] • Acute Respiratory Distress Syndrome [see Warnings and Precautions ( 5.2 )] • Serious Allergic Reactions [see Warnings and Precautions ( 5.3 )] • Use in Patients with Sickle Cell Disorders [see Warnings and Precautions ( 5.4 )] • Glomerulonephritis [see Warnings and Precautions ( 5.5 )] • Leukocytosis [see Warnings and Precautions ( 5.6 )] • Thrombocytopenia [see Warnings and Precautions ( 5.7 )] • Capillary Leak Syndrome [see Warnings and Precautions ( 5.8 )] • Potential for Tumor Growth Stimulatory Effects on Malignant Cells [see Warnings and Precautions ( 5.9 )] • Myelodysplastic syndrome [see Warnings and Precautions ( 5.10 )] • Acute myeloid leukemia [see Warnings and Precautions ( 5.10 )] • Aortitis [see Warnings and Precautions ( 5.11 )] Most common adverse reactions (≥ 5% difference in incidence compared to placebo) are bone pain and pain in extremity. ( 6.1 ) *Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of ZIEXTENZO has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Pegfilgrastim clinical trials safety data are based upon 932 patients receiving pegfilgrastim in seven randomized clinical trials. The population was 21 to 88 years of age and 92% female. The ethnicity was 75% Caucasian, 18% Hispanic, 5% Black, and 1% Asian. Patients with breast (n = 823), lung and thoracic tumors (n = 53) and lymphoma (n = 56) received pegfilgrastim after nonmyeloablative cytotoxic chemotherapy. Most patients received a single 100 mcg/kg (n = 259) or a single 6 mg (n = 546) dose per chemotherapy cycle over 4 cycles. The following adverse reaction data in Table 2 are from a randomized, double-blind, placebo-controlled study in patients with metastatic or non-metastatic breast cancer receiving docetaxel 100 mg/m 2 every 21 days (Study 3). A total of 928 patients were randomized to receive either 6 mg pegfilgrastim (n = 467) or placebo (n = 461). The patients were 21 to 88 years of age and 99% female. The ethnicity was 66% Caucasian, 31% Hispanic, 2% Black, and < 1% Asian, Native American, or other. The most common adverse reactions occurring in ≥ 5% of patients and with a between-group difference of ≥ 5% higher in the pegfilgrastim arm in placebo-controlled clinical trials are bone pain and pain in extremity. Table 2. Adverse Reactions with ≥ 5% Higher Incidence in Pegfilgrastim Patients Compared to Placebo in Study 3 Body System Adverse Reaction Placebo (N = 461) Pegfilgrastim 6 mg SC on Day 2 (N = 467) Musculoskeletal and connective tissue disorders Bone pain 26% 31% Pain in extremity 4% 9% Leukocytosis In clinical studies, leukocytosis (WBC counts > 100 x 10 9 /L) was observed in less than 1% of 932 patients with non-myeloid malignancies receiving pegfilgrastim. No complications attributable to leukocytosis were reported in clinical studies. 6.2 Immunogenicity The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of pegfilgrastim or of other pegfilgrastim products. Binding antibodies to pegfilgrastim were detected using a BIAcore assay. The approximate limit of detection for this assay is 500 ng/mL. Pre-existing binding antibodies were detected in approximately 6% (51/849) of patients with metastatic breast cancer. Four of 521 pegfilgrastim-treated subjects who were negative at baseline developed binding antibodies to pegfilgrastim following treatment. None of these 4 patients had evidence of neutralizing antibodies detected using a cell-based bioassay. 6.3 Postmarketing Experience The following adverse reactions have been identified during post approval use of pegfilgrastim products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. • Splenic rupture and splenomegaly (enlarged spleen) [see Warnings and Precautions ( 5.1 )] • Acute respiratory distress syndrome (ARDS) [see Warnings and Precautions ( 5.2 )] • Allergic reactions/hypersensitivity, including anaphylaxis, skin rash, urticaria, generalized erythema, and flushing [see Warnings and Precautions ( 5.3 )] • Sickle cell crisis [see Warnings and Precautions ( 5.4 )] • Glomerulonephritis [see Warnings and Precautions ( 5.5 )] • Leukocytosis [see Warnings and Precautions ( 5.6 )] • Thrombocytopenia [see Warnings and Precautions ( 5.7 )] • Capillary Leak Syndrome [see Warnings and Precautions ( 5.8 )] • Injection site reactions • Sweet’s syndrome (acute febrile neutrophilic dermatosis), cutaneous vasculitis • Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with breast and lung cancer receiving chemotherapy and/or radiotherapy [see Warnings and Precautions ( 5.10 )] • Aortitis [see Warnings and Precautions ( 5.11 )] • Alveolar hemorrhage"],"contraindications":["4 CONTRAINDICATIONS ZIEXTENZO is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products. Reactions have included anaphylaxis [see Warnings and Precautions ( 5.3 )] . Patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as pegfilgrastim products or filgrastim products. ( 4 )"],"mechanism_of_action":["12.1 Mechanism of Action Pegfilgrastim products are colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation."],"instructions_for_use":["Instructions for Use ZIEXTENZO ® (pegfilgrastim-bmez) injection Single-dose prefilled syringe with needle guard Guide to Parts Before use Figure A: Before use. The ZIEXTENZO prefilled syringe with needle guard not activated Important: The needle is covered by the needle cap before use. After use Figure B: After Use. The ZIEXTENZO prefilled syringe with needle guard activated. Important information: Read the Patient Information that comes with ZIEXTENZO for important information you need to know about ZIEXTENZO before using these Instructions for Use. Storing the ZIEXTENZO prefilled syringe • Store ZIEXTENZO in a refrigerator between 36°F to 46°F (2°C to 8°C). • Store ZIEXTENZO prefilled syringe in its outer carton to protect it from light or physical damage. • Take ZIEXTENZO out of the refrigerator at least 15 to 30 minutes before use to allow it to reach room temperature before preparing the injection. • Avoid freezing. If ZIEXTENZO is accidentally frozen, thaw in the refrigerator before injecting. • Do not use a ZIEXTENZO prefilled syringe that has been frozen more than 1 time. Use a new ZIEXTENZO prefilled syringe. • Throw away (dispose of) any ZIEXTENZO that has been left at room temperature 68°F to 95°F (20°C to 35°C) for more than 120 hours. See “14. Disposing of used syringes”. Keep ZIEXTENZO and all medicines out of the reach of children. Important information: • It is important that you do not try to give the injection unless you or your caregiver have received training from your healthcare provider. • Make sure that the name ZIEXTENZO appears on the carton and prefilled syringe label. • Check the carton and prefilled syringe label to make sure the dose strength is 6 mg/0.6 mL. • You should not inject a dose of ZIEXTENZO to children weighing less than 45 kg from a ZIEXTENZO prefilled syringe. A dose less than 0.6 mL (6 mg) cannot be accurately measured using the ZIEXTENZO prefilled syringe. • Do not use a ZIEXTENZO prefilled syringe after the expiration date on the label. • Do not open the outer carton until you are ready to use the ZIEXTENZO prefilled syringe. Do not use the ZIEXTENZO prefilled syringe if the seal of the tray is broken, as it may not be safe for you to use. • Do not use the ZIEXTENZO prefilled syringe if there is liquid in the plastic tray. Do not use the ZIEXTENZO pre-filled syringe if the needle cap is missing or not securely attached. In all these instances, return the entire product pack to the pharmacy. • Do not use a prefilled syringe if it has been dropped on a hard surface. The prefilled syringe may be broken even if you cannot see the break. Use a new prefilled syringe. • Do not shake the ZIEXTENZO prefilled syringe. • Be careful not to touch the needle guard wings before use. Touching them may cause the needle guard to be activated too early. • Do not try to activate the needle safety guard before the injection. • Do not remove the needle cap until just before you give the injection. • Do not reuse a ZIEXTENZO prefilled syringe. Throw away (dispose of) used syringes right away after use in a sharps disposal container. See “14. Disposing of used syringes”. Call your healthcare provider if you have any questions. Prepare the injection. 1. Find a clean, flat, well-lit work surface. 2. Remove the carton from the refrigerator and check the expiration date printed on the carton. 3. Remove the tray containing a ZIEXTENZO prefilled syringe from the carton and place it unopened on your clean work surface for at least 15 to 30 minutes, so that it can reach room temperature. • Do not use the prefilled syringe if the carton is damaged. • Do not try to warm the prefilled syringe by using a heat source such as hot water or a microwave. • Do not leave the prefilled syringe in direct sunlight. • Do not shake the prefilled syringe. 4. Wash your hands well with soap and water. Gather the following supplies for the injection (See Figure C): • 1 alcohol wipe • 1 cotton ball or gauze pad • 1 sharps disposal container • 1 adhesive bandage Figure C 5. Open the tray by peeling away the cover. Remove the ZIEXTENZO prefilled syringe from the tray by grabbing the transparent safety guard ( See Figure D ). For safety reasons: • Do not grab the plunger rod. • Do not grab the gray needle cap. Figure D Check to be sure that the plastic clear needle guard is located over the barrel of the glass syringe. If the clear needle guard is covering the needle cap, as shown in Figure B above, the needle guard has been activated. Do not try to use this prefilled syringe . Throw away (dispose of) this prefilled syringe. See “14. Disposing of used syringes” . Start over with a new prefilled syringe. Inspect the prefilled syringe and medicine (See Figure E). Figure E 6. Make sure that the medicine in the prefilled syringe is clear and colorless to slightly yellowish. You may see small air bubbles in the liquid. This is normal. Do not use the prefilled syringe if: o the medicine looks discolored or cloudy o the medicine contains lumps, flakes, or particles o it appears used or damaged o the needle cap is missing or not securely attached o the expiration date printed on the label has passed In all cases, use a new prefilled syringe and call your healthcare provider. Select and clean the injection site Figure F You can use ( See Figure F and Figure G ): • the front of your thighs • stomach-area (abdomen), except for a 2 inch area right around the navel (belly button) • upper outer area of the buttocks (only if someone else is giving you the injection • outer area of upper arm (only if someone else is giving you the injection) Choose a different site each time you give yourself an injection. Do not inject again in the exact same spot. Do not inject into areas where the skin is tender, bruised, red, scaly or hard. Avoid areas with scars or stretch marks. Figure G 7. Clean the injection site with an alcohol wipe. Let the skin dry. Do not touch the cleaned area again before injecting. Prepare the ZIEXTENZO prefilled syringe for use Figure H 8. Hold the prefilled syringe by the syringe barrel. Carefully pull the needle cap straight off to remove it from the ZIEXTENZO prefilled syringe ( See Figure H ). • Do not twist or bend the gray needle cap. • Do not hold the prefilled syringe by the plunger rod. Throw away the needle cap in your household trash. Do not put the needle cap back onto the prefilled syringe. You may see a drop of liquid at the end of the needle. This is normal. Figure I 9. With your other hand, gently pinch the skin at the injection site to create a firm surface. Insert the needle into the skin at an angle of 45 to 90 degrees, as shown ( See Figure I ). Push the needle all the way in to ensure that the medicine can be fully injected. Figure J 10. Hold the ZIEXTENZO prefilled syringe as shown ( See Figure J ). Slowly press down the plunger head as far as it will go until the plunger head is completely between the needle guard wings. Important : Keep the skin pinched while injecting. Figure K 11. Keep the plunger fully pressed down while you carefully pull the needle straight out from the injection site and off your skin ( See Figure K ). Figure L 12. Slowly release the plunger and allow the syringe needle guard to automatically cover the exposed needle ( See Figure L ). 13. There may be a small amount of blood at the injection site. You can press a cotton ball or gauze pad onto the injection site. Do not rub the injection site. Apply an adhesive bandage if needed. 14. Disposing of used syringes Figure M Put the used syringes in an FDA-cleared sharps disposal container right away after use ( See Figure M ). Do not throw away the syringe in the household trash. • If you do not have an FDA-cleared sharps disposal container, you may use a household container that is: o made of a heavy-duty plastic o can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out o upright and stable during use o leak-resistant o properly labeled to warn of hazardous waste inside the container. • When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal . • Do not reuse the prefilled syringe. • Do not recycle prefilled syringes or sharps disposal container or throw them into household trash. Important: Keep the sharps disposal container out of the reach of children. This Instructions for Use has been approved by the U.S. Food and Drug Administration. Manufactured by: Sandoz Inc. Princeton, NJ 08540 US License No. 2003. Revised: Dec 2023 IFU-Fig-A IFU-Fig-B IFU-Fig-C IFU-Fig-D IFU-Fig-E IFU-Fig-F IFU-Fig-G IFU-Fig-H IFU-Fig-I IFU-Fig-J IFU-Fig-K IFU-Fig-L IFU-Fig-M"],"recent_major_changes":["Indications and Usage, Patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome ( 1.2 ) 02/2024 Dosage and Administration, Patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome ( 2.2 ) 02/2024"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Pegfilgrastim products are colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. 12.2 Pharmacodynamics Animal data and clinical data in humans suggest a correlation between pegfilgrastim products’ exposure and the duration of severe neutropenia as a predictor of efficacy. Selection of the dosing regimen of ZIEXTENZO is based on reducing the duration of severe neutropenia. 12.3 Pharmacokinetics The pharmacokinetics of pegfilgrastim was studied in 379 patients with cancer. The pharmacokinetics of pegfilgrastim was nonlinear, and clearance decreased with increases in dose. Neutrophil receptor binding is an important component of the clearance of pegfilgrastim, and serum clearance is directly related to the number of neutrophils. In addition to numbers of neutrophils, body weight appeared to be a factor. Patients with higher body weights experienced higher systemic exposure to pegfilgrastim after receiving a dose normalized for body weight. A large variability in the pharmacokinetics of pegfilgrastim was observed. The half-life of pegfilgrastim ranged from 15 to 80 hours after subcutaneous injection. Specific Populations No gender-related differences were observed in the pharmacokinetics of pegfilgrastim, and no differences were observed in the pharmacokinetics of geriatric patients (≥ 65 years of age) compared with younger patients (< 65 years of age) [see Use in Specific Populations ( 8.5 )]. Renal Impairment In a study of 30 subjects with varying degrees of renal dysfunction, including end stage renal disease, renal dysfunction had no effect on the pharmacokinetics of pegfilgrastim. Pediatric Patients with Cancer Receiving Myelosuppressive Chemotherapy The pharmacokinetics and safety of pegfilgrastim were studied in 37 pediatric patients with sarcoma in Study 4 [see Clinical Studies 14.1 ] . The mean (± standard deviation [SD]) systemic exposure (AUC 0-inf ) of pegfilgrastim after subcutaneous administration at 100 mcg/kg was 47.9 (± 22.5) mcg·hr/mL in the youngest age group (0 to 5 years, n = 11), 22.0 (± 13.1) mcg·hr/mL in the 6 to 11 years age group (n = 10), and 29.3 (± 23.2) mcg·hr/mL in the 12 to 21 years age group (n = 13). The terminal elimination half-lives of the corresponding age groups were 30.1 (± 38.2) hours, 20.2 (± 11.3) hours, and 21.2 (± 16.0) hours, respectively. Patients Acutely Exposed to Myelosuppressive Doses of Radiation The pharmacokinetics of pegfilgrastim products is not available in patients acutely exposed to myelosuppressive doses of radiation. Based on limited pharmacokinetic data in irradiated non-human primates, the area under the concentration-time curve (AUC), reflecting the exposure to pegfilgrastim in non-human primates following a 300 mcg/kg dose of pegfilgrastim, appears to be greater than in humans receiving a 6 mg dose. Results from population modeling and simulation indicate that two 6 mg doses of pegfilgrastim administered one week apart in adults result in clinically relevant effects on duration of grade 3 and 4 neutropenia. In addition, weight based dosing in pediatric patients weighing less than 45 kg [ see Dosage and Administration, Section 2.3 , Table 1 ] provides exposures comparable to those in adults receiving two 6 mg doses one week apart."],"indications_and_usage":["1 INDICATIONS AND USAGE ZIEXTENZO is a leukocyte growth factor indicated to • Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1.1 ) • Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). ( 1.2 ) Limitations of Use ZIEXTENZO is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy ZIEXTENZO is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia [see Clinical Studies ( 14.1 )]. Limitations of Use ZIEXTENZO is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. 1.2 Patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome ZIEXTENZO is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation [see Dosage and Administration ( 2.2 ) and Clinical Studies ( 14.2 )]."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture. ( 5.1 ) • Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever, lung infiltrates, or respiratory distress. Discontinue ZIEXTENZO in patients with ARDS. ( 5.2 ) • Serious allergic reactions, including anaphylaxis: Permanently discontinue ZIEXTENZO in patients with serious allergic reactions. ( 5.3 ) • Fatal sickle cell crises: Discontinue ZIEXTENZO if sickle cell crisis occurs. ( 5.4 ) • Glomerulonephritis: Evaluate and consider dose-reduction or interruption of ZIEXTENZO if causality is likely. ( 5.5 ) • Thrombocytopenia: Monitor platelet counts. ( 5.7 ) • Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): Monitor patients with breast and lung cancer using ZIEXTENZO in conjunction with chemotherapy and/or radiotherapy for signs and symptoms of MDS/AML. ( 5.10 ) 5.1 Splenic Rupture Splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim products. Evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving ZIEXTENZO. 5.2 Acute Respiratory Distress Syndrome Acute respiratory distress syndrome (ARDS) can occur in patients receiving pegfilgrastim products. Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving ZIEXTENZO, for ARDS. Discontinue ZIEXTENZO in patients with ARDS. 5.3 Serious Allergic Reactions Serious allergic reactions, including anaphylaxis, can occur in patients receiving pegfilgrastim products. The majority of reported events occurred upon initial exposure. Allergic reactions, including anaphylaxis, can recur within days after the discontinuation of initial anti-allergic treatment. Permanently discontinue ZIEXTENZO in patients with serious allergic reactions. Do not administer ZIEXTENZO to patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products. 5.4 Use in Patients with Sickle Cell Disorders Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim products. Discontinue ZIEXTENZO if sickle cell crisis occurs. 5.5 Glomerulonephritis Glomerulonephritis has occurred in patients receiving pegfilgrastim products. The diagnoses were based upon azotemia, hematuria (microscopic and macroscopic), proteinuria, and renal biopsy. Generally, events of glomerulonephritis resolved after dose-reduction or discontinuation of pegfilgrastim products. If glomerulonephritis is suspected, evaluate for cause. If causality is likely, consider dose-reduction or interruption of ZIEXTENZO. 5.6 Leukocytosis White blood cell (WBC) counts of 100 x 10 9 /L or greater have been observed in patients receiving pegfilgrastim products. Monitoring of complete blood count (CBC) during ZIEXTENZO therapy is recommended. 5.7 Thrombocytopenia Thrombocytopenia has been reported in patients receiving pegfilgrastim products. Monitor platelet counts. 5.8 Capillary Leak Syndrome Capillary leak syndrome has been reported after G-CSF administration, including pegfilgrastim products, and is characterized by hypotension, hypoalbuminemia, edema and hemoconcentration. Episodes vary in frequency, severity and may be life-threatening if treatment is delayed. Patients who develop symptoms of capillary leak syndrome should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care. 5.9 Potential for Tumor Growth Stimulatory Effects on Malignant Cells The granulocyte colony-stimulating factor (G-CSF) receptor through which pegfilgrastim products and filgrastim products act has been found on tumor cell lines. The possibility that pegfilgrastim products act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which pegfilgrastim products are not approved, cannot be excluded. 5.10 Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) in Patients with Breast and Lung Cancer MDS and AML have been associated with the use of pegfilgrastim products in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer. Monitor patients for signs and symptoms of MDS/AML in these settings. 5.11 Aortitis Aortitis has been reported in patients receiving pegfilgrastim products. It may occur as early as the first week after start of therapy. Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (e.g., c-reactive protein and white blood cell count). Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue ZIEXTENZO if aortitis is suspected. 5.12 Nuclear Imaging Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. This should be considered when interpreting bone imaging results."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No carcinogenicity or mutagenesis studies have been performed with pegfilgrastim products. Pegfilgrastim did not affect reproductive performance or fertility in male or female rats at cumulative weekly doses approximately 6 to 9 times higher than the recommended human dose (based on body surface area)."],"adverse_reactions_table":["<table styleCode=\"Noautorules\" width=\"528.3pt\"><caption>Table 2. Adverse Reactions with &#x2265; 5% Higher Incidence in Pegfilgrastim Patients Compared to Placebo in Study 3</caption><col width=\"35%\"/><col width=\"33%\"/><col width=\"33%\"/><thead><tr><th align=\"left\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><content styleCode=\"bold\"> Body System</content> <content styleCode=\"bold\">Adverse Reaction</content></th><th align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><content styleCode=\"bold\"> Placebo (N = 461)</content></th><th align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><content styleCode=\"bold\">Pegfilgrastim 6 mg SC on Day 2 (N = 467)</content></th></tr></thead><tbody><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>Musculoskeletal and connective tissue disorders</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>Bone pain</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph>26%</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph>31%</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph>Pain in extremity</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph>4%</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph>9%</paragraph></td></tr></tbody></table>"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use). Advise patients of the following risks and potential risks with ZIEXTENZO: • Splenic rupture and splenomegaly • Acute Respiratory Distress Syndrome • Serious allergic reactions • Sickle cell crisis • Glomerulonephritis • Increased risk of Myelodysplastic Syndrome and/or Acute Myeloid Leukemia in patients with breast and lung cancer who receive ZIEXTENZO in conjunction with chemotherapy and/or radiation therapy • Capillary Leak Syndrome • Aortitis Advise patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome) that efficacy studies of pegfilgrastim products for this indication could not be conducted in humans for ethical and feasibility reasons and that, therefore, approval of this use was based on efficacy studies conducted in animals [see Clinical Studies ( 14.2 )]. Instruct patients who self-administer ZIEXTENZO using the single-dose prefilled syringe of the: • Importance of following the Instructions for Use (see Instructions for Use). • Dangers of reusing syringes. • Importance of following local requirements for proper disposal of used syringes. Manufactured by: Sandoz Inc. Princeton, NJ 08540 US License No. 2003"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Patients with cancer receiving myelosuppressive chemotherapy • 6 mg administered subcutaneously once per chemotherapy cycle. ( 2.1 ) • Do not administer between 14 days before and 24 hours after administration of cytotoxic chemotherapy. ( 2.1 ) • Use weight based dosing for pediatric patients weighing less than 45 kg; refer to Table 1. ( 2.3 ) Patients acutely exposed to myelosuppressive doses of radiation • Two doses, 6 mg each, administered subcutaneously one week apart. Administer the first dose as soon as possible after suspected or confirmed exposure to myelosuppressive doses of radiation, and a second dose one week after. ( 2.2 ) • Use weight based dosing for pediatric patients weighing less than 45 kg; refer to Table 1. ( 2.3 ) 2.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy The recommended dosage of ZIEXTENZO is a single subcutaneous injection of 6 mg administered once per chemotherapy cycle. For dosing in pediatric patients weighing less than 45 kg, refer to Table 1. Do not administer ZIEXTENZO between 14 days before and 24 hours after administration of cytotoxic chemotherapy. 2.2 Patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome The recommended dose of ZIEXTENZO is two doses, 6 mg each, administered subcutaneously one week apart. For dosing in pediatric patients weighing less than 45 kg, refer to Table 1. Administer the first dose as soon as possible after suspected or confirmed exposure to radiation levels greater than 2 gray (Gy). Administer the second dose one week after the first dose. Obtain a baseline complete blood count (CBC). Do not delay administration of ZIEXTENZO if a CBC is not readily available. Estimate a patient’s absorbed radiation dose (i.e., level of radiation exposure) based on information from public health authorities, biodosimetry if available, or clinical findings such as time to onset of vomiting or lymphocyte depletion kinetics. 2.3 Administration ZIEXTENZO is administered subcutaneously via a single-dose prefilled syringe for manual use. Prior to use‚ remove the carton from the refrigerator and allow the ZIEXTENZO prefilled syringe to reach room temperature for a minimum of 15-30 minutes. Discard any prefilled syringe left at room temperature for greater than 120 hours. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. ZIEXTENZO is supplied as a clear and colorless to slightly yellowish solution. Do not administer ZIEXTENZO if discoloration or particulates are observed. The ZIEXTENZO syringe plunger stopper and needle cap are not made with natural rubber latex. Pediatric Patients weighing less than 45 kg The ZIEXTENZO prefilled syringe is not designed to allow for direct administration of doses less than 0.6 mL (6 mg). The syringe does not bear graduation marks, which are necessary to accurately measure doses of ZIEXTENZO less than 0.6 mL (6 mg) for direct administration to patients. Thus, the direct administration to patients requiring dosing of less than 0.6 mL (6 mg) is not recommended due to the potential for dosing errors. Refer to Table 1. Table 1. Dosing of ZIEXTENZO for pediatric patients weighing less than 45 kg Body Weight ZIEXTENZO Dose Volume to Administer Less than 10 kg For pediatric patients weighing less than 10 kg, administer 0.1 mg/kg (0.01 mL/kg) of ZIEXTENZO. See below See below 10 - 20 kg 1.5 mg 0.15 mL 21 - 30 kg 2.5 mg 0.25 mL 31 - 44 kg 4 mg 0.4 mL"],"spl_product_data_elements":["ZIEXTENZO pegfilgrastim-bmez PEGFILGRASTIM PEGFILGRASTIM ACETIC ACID POLYSORBATE 20 SORBITOL SODIUM HYDROXIDE WATER"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS ZIEXTENZO is a clear, colorless to slightly yellowish, preservative-free solution available as: • Injection: 6 mg/0.6 mL in a single-dose prefilled syringe for manual use only. Injection: 6 mg/0.6 mL solution in a single-dose prefilled syringe for manual use only. ( 3 )"],"instructions_for_use_table":["<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"44%\"/><col width=\"48%\"/><tbody><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>1 alcohol wipe</item><item><caption>&#x2022;</caption>1 cotton ball or gauze pad</item><item><caption>&#x2022;</caption>1 sharps disposal container</item><item><caption>&#x2022;</caption>1 adhesive bandage</item></list></td><td align=\"center\" valign=\"top\"><renderMultiMedia ID=\"ID0E4CGK\" referencedObject=\"ID0E3CGK\"/><paragraph><content styleCode=\"bold\">Figure C</content></paragraph></td></tr></tbody></table>","<table styleCode=\"Noautorules\" width=\"522pt\"><col width=\"35%\"/><col width=\"65%\"/><tbody><tr><td valign=\"top\"><renderMultiMedia ID=\"id-775948801\" referencedObject=\"d2fff3af-67fa-406b-a769-63ff64581bed\"/><paragraph><content styleCode=\"bold\">Figure F</content></paragraph><renderMultiMedia ID=\"id414437516\" referencedObject=\"ID_6b0e3cb6-0567-48a4-81a8-cf06c053896f\"/></td><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>You can use (<content styleCode=\"bold\">See Figure F</content> and <content styleCode=\"bold\">Figure G</content>):</item></list><list listType=\"unordered\"><item><caption>&#x2022;</caption>the front of your thighs </item><item><caption>&#x2022;</caption>stomach-area (abdomen), except for a 2 inch area right around the navel (belly button)</item><item><caption>&#x2022;</caption>upper outer area of the buttocks (only if someone else is giving you the injection</item><item><caption>&#x2022;</caption>outer area of upper arm (only if someone else is giving you the injection)</item></list><paragraph>Choose a different site each time you give yourself an injection. <content styleCode=\"bold\">Do not</content> inject again in the exact same spot.</paragraph><paragraph><content styleCode=\"bold\">Do not</content> inject into areas where the skin is tender, bruised, red, scaly or hard. Avoid areas with scars or stretch marks.</paragraph></td></tr></tbody></table>","<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"36%\"/><col width=\"64%\"/><tbody><tr><td valign=\"top\"><renderMultiMedia ID=\"id1912736257\" referencedObject=\"ID_64c5620f-e831-4ea1-945f-97c71d3b49ce\"/><paragraph><content styleCode=\"bold\"> Figure H</content></paragraph></td><td valign=\"top\"><list listType=\"ordered\"><item><caption>8.</caption>Hold the prefilled syringe by the syringe barrel. Carefully pull the needle cap straight off to remove it from the ZIEXTENZO prefilled syringe (<content styleCode=\"bold\">See Figure H</content>). </item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Do not</content> twist or bend the gray needle cap.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Do not</content> hold the prefilled syringe by the plunger rod.</item><item><caption> </caption>Throw away the needle cap in your household trash. <content styleCode=\"bold\">Do not </content>put the needle cap back onto the prefilled syringe. </item><item><caption> </caption>You may see a drop of liquid at the end of the needle. This is normal.</item></list></td></tr><tr><td valign=\"top\"><renderMultiMedia ID=\"id323397429\" referencedObject=\"ID_28b93208-3b5a-4996-a6a2-2f5aebf9b59f\"/><paragraph><content styleCode=\"bold\">Figure I</content></paragraph></td><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>9. With your other hand, gently pinch the skin at the injection site to create a firm surface. Insert the needle into the skin at an angle of 45 to 90 degrees, as shown (<content styleCode=\"bold\">See Figure I</content>). Push the needle all the way in to ensure that the medicine can be fully injected.</item></list></td></tr><tr><td valign=\"top\"><renderMultiMedia ID=\"id-104039823\" referencedObject=\"ID_0503236a-f1b1-443a-91b1-16e929f31a66\"/><paragraph><content styleCode=\"bold\">Figure J</content></paragraph></td><td valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>10. Hold the ZIEXTENZO prefilled syringe as shown (<content styleCode=\"bold\">See Figure J</content>). Slowly press down the plunger head as far as it will go until the plunger head is completely between the needle guard wings.</item><item><caption> </caption></item><item><caption> </caption><content styleCode=\"bold\">Important</content>: Keep the skin pinched while injecting.</item></list></td></tr><tr><td valign=\"top\"><renderMultiMedia ID=\"id1446426049\" referencedObject=\"ID_59d1af6d-d17a-4305-a870-244e6c0816f2\"/><paragraph><content styleCode=\"bold\">Figure K</content></paragraph></td><td valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>11. Keep the plunger fully pressed down while you carefully pull the needle straight out from the injection site and off your skin (<content styleCode=\"bold\">See Figure K</content>).</item></list></td></tr><tr><td valign=\"top\"><renderMultiMedia ID=\"id379289790\" referencedObject=\"c1580083-8edd-4c7c-a7f9-d7966f070e7a\"/><paragraph><content styleCode=\"bold\">Figure L</content></paragraph></td><td valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>12. Slowly release the plunger and allow the syringe needle guard to automatically cover the exposed needle (<content styleCode=\"bold\">See Figure L</content>).</item><item><caption> </caption></item><item><caption> </caption>13. There may be a small amount of blood at the injection site. You can press a cotton ball or gauze pad onto the injection site. Do not rub the injection site. Apply an adhesive bandage if needed.</item></list></td></tr></tbody></table>","<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"43%\"/><col width=\"57%\"/><tbody><tr><td align=\"left\" valign=\"top\"><renderMultiMedia ID=\"id194507153\" referencedObject=\"ID_918d47c3-8514-40cf-a504-ade206423864\"/><paragraph><content styleCode=\"bold\"> Figure M</content></paragraph></td><td align=\"left\" valign=\"top\"><paragraph>Put the used syringes in an FDA-cleared sharps disposal container right away after use (<content styleCode=\"bold\">See Figure M</content>). <content styleCode=\"bold\">Do not</content> throw away the syringe in the household trash.</paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:<list listType=\"unordered\"><item><caption>o</caption>made of a heavy-duty plastic</item><item><caption>o</caption>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out</item><item><caption>o</caption>upright and stable during use</item><item><caption>o</caption>leak-resistant</item><item><caption>o</caption>properly labeled to warn of hazardous waste inside the container.</item></list></item><item><caption>&#x2022;</caption>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA&#x2019;s website at: <linkHtml href=\"http://www.fda.gov/safesharpsdisposal\">http://www.fda.gov/safesharpsdisposal</linkHtml>.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Do not</content> reuse the prefilled syringe.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Do not</content> recycle prefilled syringes or sharps disposal container or throw them into household trash. </item></list><paragraph><content styleCode=\"bold\">Important: </content>Keep the sharps disposal container out of the reach of children. </paragraph></td></tr></tbody></table>"],"spl_patient_package_insert":["Patient Information ZIEXTENZO (zee-eks-TEN-zoh) (pegfilgrastim-bmez) injection Single-dose prefilled syringe What is ZIEXTENZO? ZIEXTENZO is a man-made form of granulocyte colony-stimulating factor (G-CSF). G-CSF is a substance produced by the body. It stimulates the growth of neutrophils, a type of white blood cell important in the body’s fight against infection. Acute Radiation Syndrome: The effectiveness of pegfilgrastim for this use was only studied in animals, because it could not be studied in people. Do not take ZIEXTENZO if you have had a serious allergic reaction to pegfilgrastim products or filgrastim products. Before you receive ZIEXTENZO, tell your healthcare provider about all of your medical conditions, including if you: • have a sickle cell disorder. • have kidney problems. • are pregnant or plan to become pregnant. It is not known if ZIEXTENZO will harm your unborn baby. • are breastfeeding or plan to breastfeed. It is not known if ZIEXTENZO passes into your breast milk. Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. How will I receive ZIEXTENZO? • ZIEXTENZO is given as an injection under your skin (subcutaneous injection) by a healthcare provider. If your healthcare provider decides that the subcutaneous injections can be given at home by you or your caregiver, follow the detailed “Instructions for Use” that comes with your ZIEXTENZO for information on how to prepare and inject a dose of ZIEXTENZO. • You and your caregiver will be shown how to prepare and inject ZIEXTENZO before you use it. • You should not inject a dose of ZIEXTENZO to children weighing less than 45 kg from a ZIEXTENZO prefilled syringe. A dose less than 0.6 mL (6 mg) cannot be accurately measured using the ZIEXTENZO prefilled syringe. • If you are receiving ZIEXTENZO because you are also receiving chemotherapy, the last dose of ZIEXTENZO should be injected at least 14 days before and 24 hours after your dose of chemotherapy. • If you miss a dose of ZIEXTENZO, talk to your healthcare provider about when you should give your next dose. What are possible side effects of ZIEXTENZO? ZIEXTENZO may cause serious side effects, including: • Spleen Rupture. Your spleen may become enlarged and can rupture. A ruptured spleen can cause death. Call your healthcare provider right away if you have pain in the left upper stomach area or your left shoulder. • A serious lung problem called Acute Respiratory Distress Syndrome (ARDS). Call your healthcare provider or get emergency help right away if you have shortness of breath with or without a fever, trouble breathing, or a fast rate of breathing. • Serious allergic reactions. ZIEXTENZO can cause serious allergic reactions. These reactions can cause a rash over your whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate, and sweating. If you have any of these symptoms, stop using ZIEXTENZO and call your healthcare provider or get emergency medical help right away. • Sickle cell crises. You may have a serious sickle cell crisis, which could lead to death, if you have a sickle cell disorder and receive ZIEXTENZO. Call your healthcare provider right away if you have symptoms of sickle cell crisis such as pain or difficulty breathing. • Kidney injury (glomerulonephritis). ZIEXTENZO can cause kidney injury. Call your healthcare provider right away if you develop any of the following symptoms: o swelling of your face or ankles o blood in your urine or dark colored urine o you urinate less than usual • Increased white blood cell count (leukocytosis). Your healthcare provider will check your blood during treatment with ZIEXTENZO. • Decreased platelet count (thrombocytopenia). Your healthcare provider will check your blood during treatment with ZIEXTENZO. Tell your healthcare provider if you have unusual bleeding or bruising during treatment with ZIEXTENZO. This could be a sign of decreased platelet counts, which may reduce the ability of your blood to clot. • Capillary Leak Syndrome. ZIEXTENZO can cause fluid to leak from blood vessels into your body’s tissues. This condition is called “Capillary Leak Syndrome” (CLS). CLS can quickly cause you to have symptoms that may become life-threatening. Get emergency medical help right away if you develop any of the following symptoms: o swelling or puffiness and are urinating less than usual o trouble breathing o swelling of your stomach area (abdomen) and feeling of fullness o dizziness or feeling faint o a general feeling of tiredness • Myelodysplastic syndrome and acute myeloid leukemia. If you have breast cancer or lung cancer, when ZIEXTENZO is used with chemotherapy and radiation therapy, or with radiation therapy alone, you may have an increased risk of developing a precancerous blood condition called myelodysplastic syndrome (MDS) or a blood cancer called acute myeloid leukemia (AML). Symptoms of MDS and AML may include tiredness, fever, and easy bruising or bleeding. Call your healthcare provider if you develop these symptoms during treatment with ZIEXTENZO. • Inflammation of the aorta (aortitis). Inflammation of the aorta (the large blood vessel which transports blood from the heart to the body) has been reported in patients who received pegfilgrastim products. Symptoms may include fever, abdominal pain, feeling tired, and back pain. Call your healthcare provider if you experience these symptoms. The most common side effects of ZIEXTENZO are pain in the bones, arms, and legs. These are not all the possible side effects of ZIEXTENZO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store ZIEXTENZO? • Store ZIEXTENZO in the refrigerator between 36°F to 46°F (2°C to 8°C). • Take ZIEXTENZO out of the refrigerator for at least 15 to 30 minutes before use and allow it to reach room temperature before preparing an injection. • Avoid freezing. If ZIEXTENZO is accidently frozen, allow the prefilled syringe to thaw in the refrigerator before injecting. • Do not use a ZIEXTENZO prefilled syringe that has been frozen more than 1 time. Use a new ZIEXTENZO prefilled syringe. • Keep the prefilled syringe in the original carton to protect from light or physical damage. • Do not shake the prefilled syringe. • Throw away (dispose of) any ZIEXTENZO that has been left at room temperature, 68°F to 95°F (20°C to 35°C), for more than 120 hours. Keep the ZIEXTENZO prefilled syringe out of the reach of children. General information about the safe and effective use of ZIEXTENZO. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ZIEXTENZO for a condition for which it was not prescribed. Do not give ZIEXTENZO to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ZIEXTENZO that is written for health professionals. What are the ingredients in ZIEXTENZO? Active ingredient: pegfilgrastim-bmez Inactive ingredients: acetic acid, polysorbate 20, sorbitol, and Water for Injection. Sodium hydroxide may be added as necessary to adjust pH. Manufactured by: Sandoz Inc. Princeton, NJ 08540 US License No. 2003 For more information, visit www.ziextenzo.com or call 1-800-525-8747 This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 02/2024"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary Although available data with ZIEXTENZO or pegfilgrastim product use in pregnant women are insufficient to establish whether there is a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes, there are available data from published studies in pregnant women exposed to filgrastim products. These studies have not established an association of filgrastim product use during pregnancy with major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal studies, no evidence of reproductive/developmental toxicity occurred in the offspring of pregnant rats that received cumulative doses of pegfilgrastim approximately 10 times the recommended human dose (based on body surface area). In pregnant rabbits, increased embryolethality and spontaneous abortions occurred at 4 times the maximum recommended human dose simultaneously with signs of maternal toxicity (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data Pregnant rabbits were dosed with pegfilgrastim subcutaneously every other day during the period of organogenesis. At cumulative doses ranging from the approximate human dose to approximately 4 times the recommended human dose (based on body surface area), the treated rabbits exhibited decreased maternal food consumption, maternal weight loss, as well as reduced fetal body weights and delayed ossification of the fetal skull; however, no structural anomalies were observed in the offspring from either study. Increased incidences of post-implantation losses and spontaneous abortions (more than half the pregnancies) were observed at cumulative doses approximately 4 times the recommended human dose, which were not seen when pregnant rabbits were exposed to the recommended human dose. Three studies were conducted in pregnant rats dosed with pegfilgrastim at cumulative doses up to approximately 10 times the recommended human dose at the following stages of gestation: during the period of organogenesis, from mating through the first half of pregnancy, and from the first trimester through delivery and lactation. No evidence of fetal loss or structural malformations was observed in any study. Cumulative doses equivalent to approximately 3 and 10 times the recommended human dose resulted in transient evidence of wavy ribs in fetuses of treated mothers (detected at the end of gestation but no longer present in pups evaluated at the end of lactation). 8.2 Lactation Risk Summary There are no data on the presence of pegfilgrastim products in human milk, the effects on the breastfed child, or the effects on milk production. Other filgrastim products are secreted poorly into breast milk, and filgrastim products are not absorbed orally by neonates. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ZIEXTENZO and any potential adverse effects on the breastfed child from ZIEXTENZO or from the underlying maternal condition. 8.4 Pediatric Use The safety and effectiveness of ZIEXTENZO have been established in pediatric patients. No overall differences in safety were identified between adult and pediatric patients based on postmarketing surveillance and review of the scientific literature. Use of ZIEXTENZO in pediatric patients for chemotherapy-induced neutropenia is based on ZIEXTENZO’s approval as a biosimilar to pegfilgrastim and evidence from adequate and well-controlled studies of pegfilgrastim in adults with additional pharmacokinetic and safety data of pegfilgrastim in pediatric patients with sarcoma [see Clinical Pharmacology ( 12.3 ) and Clinical Studies ( 14.1 )]. The use of ZIEXTENZO to increase survival in pediatric patients acutely exposed to myelosuppressive doses of radiation is based on ZIEXTENZO’s approval as a biosimilar to pegfilgrastim and evidence from efficacy studies of pegfilgrastim conducted in animals and clinical data supporting the use of pegfilgrastim in patients with cancer receiving myelosuppressive chemotherapy. Efficacy studies of pegfilgrastim products could not be conducted in humans with acute radiation syndrome for ethical and feasibility reasons. Results from population modeling and simulation indicate that two doses of pegfilgrastim (Table 1), administered one week apart provide pediatric patients with exposures comparable to that in adults receiving two 6 mg doses one week apart [see Dosage and Administration ( 2.3 ), Clinical Pharmacology ( 12.3 ) and Clinical Studies ( 14.2 )]. 8.5 Geriatric Use Of the 932 patients with cancer who received pegfilgrastim in clinical studies, 139 (15%) were aged 65 and over, and 18 (2%) were aged 75 and over. No overall differences in safety or effectiveness were observed between patients aged 65 and older and younger patients."],"dosage_and_administration_table":["<table width=\"494.45pt\"><caption>Table 1. Dosing of ZIEXTENZO for pediatric patients weighing less than 45 kg</caption><col width=\"32%\"/><col width=\"32%\"/><col width=\"35%\"/><tbody><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Body Weight</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">ZIEXTENZO Dose</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Volume to Administer</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>Less than 10 kg<footnote ID=\"_Ref2071353\">For pediatric patients weighing less than 10 kg, administer 0.1 mg/kg (0.01 mL/kg) of ZIEXTENZO.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph>See below<footnoteRef IDREF=\"_Ref2071353\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph>See below<footnoteRef IDREF=\"_Ref2071353\"/></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>10 - 20 kg</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph>1.5 mg</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph>0.15 mL</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>21 - 30 kg</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph>2.5 mg</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph>0.25 mL</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph>31 - 44 kg</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph>4 mg</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph>0.4 mL</paragraph></td></tr></tbody></table>"],"spl_patient_package_insert_table":["<table styleCode=\"Noautorules\" width=\"540pt\"><col width=\"100%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">ZIEXTENZO (zee-eks-TEN-zoh)</content></paragraph><paragraph><content styleCode=\"bold\">(pegfilgrastim-bmez)</content></paragraph><paragraph><content styleCode=\"bold\">injection</content></paragraph><paragraph><content styleCode=\"bold\">Single-dose prefilled syringe</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What is ZIEXTENZO?</content></paragraph><paragraph>ZIEXTENZO is a man-made form of granulocyte colony-stimulating factor (G-CSF). G-CSF is a substance produced by the body. It stimulates the growth of neutrophils, a type of white blood cell important in the body&#x2019;s fight against infection.</paragraph><paragraph>Acute Radiation Syndrome: The effectiveness of pegfilgrastim for this use was only studied in animals, because it could not be studied in people.</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Do not take ZIEXTENZO</content> if you have had a serious allergic reaction to pegfilgrastim products or filgrastim products.</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption><content styleCode=\"bold\">Before you receive ZIEXTENZO, tell your healthcare provider about all of your medical conditions, including if you:</content></item><item><caption>&#x2022;</caption>have a sickle cell disorder.</item><item><caption>&#x2022;</caption>have kidney problems.</item><item><caption>&#x2022;</caption>are pregnant or plan to become pregnant. It is not known if ZIEXTENZO will harm your unborn baby.</item><item><caption>&#x2022;</caption>are breastfeeding or plan to breastfeed. It is not known if ZIEXTENZO passes into your breast milk.</item></list><paragraph><content styleCode=\"bold\">Tell your healthcare provider about all of the medicines you take, </content>including prescription and over-the-counter medicines, vitamins, and herbal supplements.</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">How will I receive ZIEXTENZO?</content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"bold\">ZIEXTENZO is given as an injection under your skin (subcutaneous injection) by a healthcare provider. If your healthcare provider decides that the subcutaneous injections can be given at home by you or your caregiver, follow the detailed &#x201C;Instructions for Use&#x201D; that comes with your ZIEXTENZO for information on how to prepare and inject a dose of ZIEXTENZO.</content></item><item><caption>&#x2022;</caption>You and your caregiver will be shown how to prepare and inject ZIEXTENZO before you use it.</item><item><caption>&#x2022;</caption>You should not inject a dose of ZIEXTENZO to children weighing less than 45 kg from a ZIEXTENZO prefilled syringe. A dose less than 0.6 mL (6 mg) cannot be accurately measured using the ZIEXTENZO prefilled syringe.</item><item><caption>&#x2022;</caption>If you are receiving ZIEXTENZO because you are also receiving chemotherapy, the last dose of ZIEXTENZO should be injected at least 14 days before and 24 hours after your dose of chemotherapy.</item><item><caption>&#x2022;</caption>If you miss a dose of ZIEXTENZO, talk to your healthcare provider about when you should give your next dose.</item></list></td></tr><tr><td align=\"justify\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What are possible side effects of ZIEXTENZO?</content></paragraph><paragraph><content styleCode=\"bold\">ZIEXTENZO may cause serious side effects, including:</content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"bold\">Spleen Rupture.</content> Your spleen may become enlarged and can rupture. A ruptured spleen can cause death. Call your healthcare provider right away if you have pain in the left upper stomach area or your left shoulder.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">A serious lung problem called Acute Respiratory Distress Syndrome (ARDS).</content> Call your healthcare provider or get emergency help right away if you have shortness of breath with or without a fever, trouble breathing, or a fast rate of breathing.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Serious allergic reactions.</content> ZIEXTENZO can cause serious allergic reactions. These reactions can cause a rash over your whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate, and sweating. If you have any of these symptoms, stop using ZIEXTENZO and call your healthcare provider or get emergency medical help right away.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Sickle cell crises.</content> You may have a serious sickle cell crisis, which could lead to death, if you have a sickle cell disorder and receive ZIEXTENZO. Call your healthcare provider right away if you have symptoms of sickle cell crisis such as pain or difficulty breathing.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Kidney injury (glomerulonephritis).</content> ZIEXTENZO can cause kidney injury. Call your healthcare provider right away if you develop any of the following symptoms:<list listType=\"unordered\"><item><caption>o</caption>swelling of your face or ankles</item><item><caption>o</caption>blood in your urine or dark colored urine</item><item><caption>o</caption>you urinate less than usual</item></list></item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Increased white blood cell count (leukocytosis). </content>Your healthcare provider will check your blood during treatment with ZIEXTENZO.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Decreased platelet count (thrombocytopenia). </content>Your healthcare provider will check your blood during treatment with ZIEXTENZO. Tell your healthcare provider if you have unusual bleeding or bruising during treatment with ZIEXTENZO. This could be a sign of decreased platelet counts, which may reduce the ability of your blood to clot.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Capillary Leak Syndrome. </content>ZIEXTENZO can cause fluid to leak from blood vessels into your body&#x2019;s tissues. This condition is called &#x201C;Capillary Leak Syndrome&#x201D; (CLS). CLS can quickly cause you to have symptoms that may become life-threatening. Get emergency medical help right away if you develop any of the following symptoms:<list listType=\"unordered\"><item><caption>o</caption>swelling or puffiness and are urinating less than usual</item><item><caption>o</caption>trouble breathing</item><item><caption>o</caption>swelling of your stomach area (abdomen) and feeling of fullness</item><item><caption>o</caption>dizziness or feeling faint</item><item><caption>o</caption>a general feeling of tiredness</item></list></item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Myelodysplastic syndrome and acute myeloid leukemia. </content>If you have breast cancer or lung cancer, when ZIEXTENZO is used with chemotherapy and radiation therapy, or with radiation therapy alone, you may have an increased risk of developing a precancerous blood condition called myelodysplastic syndrome (MDS) or a blood cancer called acute myeloid leukemia (AML). Symptoms of MDS and AML may include tiredness, fever, and easy bruising or bleeding. Call your healthcare provider if you develop these symptoms during treatment with ZIEXTENZO.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Inflammation of the aorta (aortitis). </content>Inflammation of the aorta (the large blood vessel which transports blood from the heart to the body) has been reported in patients who received pegfilgrastim products. Symptoms may include fever, abdominal pain, feeling tired, and back pain. Call your healthcare provider if you experience these symptoms.</item></list><paragraph>The most common side effects of ZIEXTENZO are pain in the bones, arms, and legs. </paragraph><paragraph>These are not all the possible side effects of ZIEXTENZO. </paragraph><paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph></td></tr><tr><td align=\"justify\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">How should I store ZIEXTENZO?</content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>Store ZIEXTENZO in the refrigerator between 36&#xB0;F to 46&#xB0;F (2&#xB0;C to 8&#xB0;C).</item><item><caption>&#x2022;</caption>Take ZIEXTENZO out of the refrigerator for at least 15 to 30 minutes before use and allow it to reach room temperature before preparing an injection.</item><item><caption>&#x2022;</caption>Avoid freezing. If ZIEXTENZO is accidently frozen, allow the prefilled syringe to thaw in the refrigerator before injecting.</item><item><caption>&#x2022;</caption>Do not use a ZIEXTENZO prefilled syringe that has been frozen more than 1 time. Use a new ZIEXTENZO prefilled syringe.</item><item><caption>&#x2022;</caption>Keep the prefilled syringe in the original carton to protect from light or physical damage.</item><item><caption>&#x2022;</caption>Do not shake the prefilled syringe.</item><item><caption>&#x2022;</caption>Throw away (dispose of) any ZIEXTENZO that has been left at room temperature, 68&#xB0;F to 95&#xB0;F (20&#xB0;C to 35&#xB0;C), for more than 120 hours.</item></list><paragraph><content styleCode=\"bold\">Keep the ZIEXTENZO prefilled syringe out of the reach of children.</content></paragraph></td></tr><tr><td align=\"justify\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">General information about the safe and effective use of ZIEXTENZO.</content></paragraph><paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ZIEXTENZO for a condition for which it was not prescribed. Do not give ZIEXTENZO to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ZIEXTENZO that is written for health professionals.</paragraph></td></tr><tr><td align=\"justify\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What are the ingredients in ZIEXTENZO? </content></paragraph><paragraph>Active ingredient: pegfilgrastim-bmez</paragraph><paragraph><content styleCode=\"bold\">Inactive ingredients:</content> acetic acid, polysorbate 20, sorbitol, and Water for Injection. Sodium hydroxide may be added as necessary to adjust pH.</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Manufactured by: Sandoz Inc. Princeton, NJ 08540 US License No. 2003</paragraph><paragraph>For more information, visit www.ziextenzo.com or call 1-800-525-8747</paragraph></td></tr></tbody></table>"],"package_label_principal_display_panel":["ZIEXTENZO 6 mg/0.6 mL Carton NDC 61314-866-02 Ziextenzo ® 6 mg/0.6 mL (pegfilgrastim-bmez) Injection For subcutaneous use only One Time Use Only One single-dose prefilled syringe with needle guard Pegylated Recombinant Methionyl Human Granulocyte Colony- Stimulating Factor (PEG-r-metHuG-CSF) derived from E coli No Preservative. The syringe plunger stopper and needle cap are not made with natural rubber latex. Rx Only SANDOZ A Novartis Division Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No carcinogenicity or mutagenesis studies have been performed with pegfilgrastim products. Pegfilgrastim did not affect reproductive performance or fertility in male or female rats at cumulative weekly doses approximately 6 to 9 times higher than the recommended human dose (based on body surface area)."]},"tags":[{"label":"Leukocyte Growth Factor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Granulocyte colony-stimulating factor receptor","category":"target"},{"label":"CSF3R","category":"gene"},{"label":"L03AA13","category":"atc"},{"label":"Subcutaneous","category":"route"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"Allogeneic peripheral blood stem cell transplant","category":"indication"},{"label":"Chemotherapy-induced neutropenia","category":"indication"},{"label":"Amgen","category":"company"},{"label":"Approved 2000s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DEVICE ADHESION ISSUE","source":"FDA FAERS","actionTaken":"11443 reports"},{"date":"","signal":"WRONG TECHNIQUE IN PRODUCT USAGE PROCESS","source":"FDA FAERS","actionTaken":"10242 reports"},{"date":"","signal":"UNINTENTIONAL MEDICAL DEVICE REMOVAL","source":"FDA FAERS","actionTaken":"8931 reports"},{"date":"","signal":"DEVICE MALFUNCTION","source":"FDA FAERS","actionTaken":"7325 reports"},{"date":"","signal":"DEVICE USE ERROR","source":"FDA FAERS","actionTaken":"6033 reports"},{"date":"","signal":"DEVICE ISSUE","source":"FDA FAERS","actionTaken":"5125 reports"},{"date":"","signal":"ACCIDENTAL EXPOSURE TO PRODUCT","source":"FDA FAERS","actionTaken":"5025 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"3835 reports"},{"date":"","signal":"FEBRILE NEUTROPENIA","source":"FDA FAERS","actionTaken":"3760 reports"},{"date":"","signal":"DEVICE OCCLUSION","source":"FDA FAERS","actionTaken":"3273 reports"}],"commonSideEffects":[{"effect":"Bone pain","drugRate":"31%","severity":"common","_validated":true},{"effect":"Pain in extremity","drugRate":"26%","severity":"common","_validated":true},{"effect":"Leukocytosis","drugRate":"reported","severity":"unknown"},{"effect":"Splenic rupture and splenomegaly","drugRate":"reported","severity":"unknown"},{"effect":"Acute respiratory distress syndrome","drugRate":"reported","severity":"unknown"},{"effect":"Allergic reactions/hypersensitivity","drugRate":"reported","severity":"unknown"},{"effect":"Sickle cell crisis","drugRate":"reported","severity":"unknown"},{"effect":"Glomerulonephritis","drugRate":"reported","severity":"unknown"},{"effect":"Thrombocytopenia","drugRate":"reported","severity":"unknown"},{"effect":"Capillary leak syndrome","drugRate":"reported","severity":"unknown"},{"effect":"Injection site reactions","drugRate":"reported","severity":"unknown"},{"effect":"Sweets syndrome","drugRate":"reported","severity":"unknown"},{"effect":"Cutaneous vasculitis","drugRate":"reported","severity":"unknown"},{"effect":"Myelodysplastic syndrome","drugRate":"reported","severity":"unknown"},{"effect":"Acute myeloid leukemia","drugRate":"reported","severity":"unknown"},{"effect":"Aortitis","drugRate":"reported","severity":"unknown"},{"effect":"Alveolar hemorrhage","drugRate":"reported","severity":"unknown"}],"specialPopulations":{"Pregnancy":"Although available data with FYLNETRA or pegfilgrastim product use in pregnant women are insufficient to establish whether there is drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes, there are available data from published studies in pregnant women exposed to filgrastim products. These studies have not established an association of filgrastim product use during pregnancy with major birth defects, miscarriage, or adverse maternal or fetal outcomes.In animal studies, no evidence of reproductive/developmental toxicity occurred in the offspring of pregnant rats that received cumulative doses of pegfilgrastim approximately 10 times the recommended human dose (based on body surface area). In pregnant rabbits, increased embryolethality and spontaneous abortions occurred at times the maximum recommended human dose simultaneously with signs of maternal toxicity (see Data).","Geriatric use":"Of the 932 patients with cancer who received pegfilgrastim in clinical studies, 139 (15%) were aged 65 and over, and 18 (2%) were aged 75 and over. No overall differences in safety or effectiveness were observed between patients aged 65 and older and younger patients.","Paediatric use":"Of the 932 patients with cancer who received pegfilgrastim in clinical studies, 139 (15%) were age 65 and over, and 18 (2%) were age 75 and over. No overall differences in safety or effectiveness were observed between patients age 65 and older and younger patients."}},"trials":[],"aliases":[],"company":"Amgen","patents":[{"type":"Biologic Exclusivity","filed":"January 31, 2002","source":"FDA Purple Book","status":"Active","expires":"November 13, 2022","territory":"US","patentNumber":"BLA 125031"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=PEGFILGRASTIM","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:23:27.906841+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T03:23:27.906422+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Pegfilgrastim","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:23:36.803583+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:23:35.515735+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T03:23:27.925517+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:23:26.506826+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PEGFILGRASTIM","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:23:36.226181+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:23:24.887792+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:23:24.887846+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:23:24.887859+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:23:37.757864+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Granulocyte colony stimulating factor receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:23:36.803354+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201568/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:23:36.716417+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"BLA761045","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:23:24.887869+00:00"}},"allNames":"neulasta","offLabel":[],"synonyms":["pegfilgrastim-jmdb","fulphila","pegfilgrastim","neulasta","ristempa","pegfilgrastim (genetical recombination)","g-lasta"],"timeline":[{"date":"2002-01-31","type":"positive","source":"DrugCentral","milestone":"FDA approval (Amgen)"},{"date":"2002-08-22","type":"positive","source":"DrugCentral","milestone":"EMA approval (Amgen Europe B.V.)"},{"date":"2014-09-26","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Kyowa Hakko Kirin Co., Ltd.)"}],"aiSummary":"Neulasta (PEGFILGRASTIM) is a leukocyte growth factor developed by AMGEN, targeting the granulocyte colony-stimulating factor receptor. It is a small molecule modality, FDA-approved in 2002 for allogeneic peripheral blood stem cell transplant and chemotherapy-induced neutropenia. As a patented product, Neulasta remains under AMGEN's ownership. Key safety considerations include potential increased risk of thrombocytopenia and leukocytosis. Neulasta's mechanism of action involves stimulating the production of white blood cells.","approvals":[{"date":"2002-01-31","orphan":false,"company":"AMGEN","regulator":"FDA"},{"date":"2002-08-22","orphan":false,"company":"Amgen Europe B.V.","regulator":"EMA"},{"date":"2014-09-26","orphan":false,"company":"Kyowa Hakko Kirin Co., Ltd.","regulator":"PMDA"}],"brandName":"Neulasta","ecosystem":[{"indication":"Allogeneic peripheral blood stem cell transplant","otherDrugs":[],"globalPrevalence":null},{"indication":"Chemotherapy-induced neutropenia","otherDrugs":[{"name":"filgrastim","slug":"filgrastim","company":"Amgen"},{"name":"sargramostim","slug":"sargramostim","company":"Berlex Labs"}],"globalPrevalence":null}],"mechanism":{"target":"Granulocyte colony-stimulating factor receptor","novelty":"Follow-on","targets":[{"gene":"CSF3R","source":"DrugCentral","target":"Granulocyte colony-stimulating factor receptor","protein":"Granulocyte colony-stimulating factor receptor"}],"modality":"Small Molecule","drugClass":"Leukocyte Growth Factor [EPC]","explanation":"Pegfilgrastim products are colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.","oneSentence":"Neulasta stimulates the production of white blood cells by binding to their receptors.","technicalDetail":"Neulasta, a pegylated form of filgrastim, acts as a granulocyte colony-stimulating factor (G-CSF) analog, binding to the G-CSF receptor on the surface of hematopoietic cells, thereby stimulating the proliferation and differentiation of these cells into mature white blood cells."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Pegfilgrastim","title":"Pegfilgrastim","extract":"Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. It serves to stimulate the production of white blood cells (neutrophils). Pegfilgrastim was developed by Amgen."},"purpleBook":{"bla":"125031","source":"FDA Purple Book","approvalDate":"January 31, 2002","licenseStatus":"Licensed","exclusivityExpiry":"November 13, 2022"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4986","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=PEGFILGRASTIM","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PEGFILGRASTIM","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Pegfilgrastim","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://purplebooksearch.fda.gov/","fields":["biologicExclusivity"],"source":"FDA Purple Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T15:16:13.150969","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:23:42.067162+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[{"form":"INJECTION","route":"SUBCUTANEOUS","company":"Amneal Pharmaceuticals LLC","brandName":"FYLNETRA","isOriginal":false,"marketingStatus":"BLA"},{"form":"INJECTION","route":"SUBCUTANEOUS","company":"Biocon Biologics Inc.","brandName":"Fulphila","isOriginal":false,"marketingStatus":"BLA"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","company":"Pfizer Laboratories Div Pfizer Inc","brandName":"NYVEPRIA","isOriginal":false,"marketingStatus":"BLA"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","company":"Fresenius Kabi USA, LLC","brandName":"STIMUFEND","isOriginal":false,"marketingStatus":"BLA"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","company":"Coherus BioSciences Inc","brandName":"UDENYCA","isOriginal":false,"marketingStatus":"BLA"},{"form":"INJECTION","route":"SUBCUTANEOUS","company":"Sandoz Inc","brandName":"ZIEXTENZO","isOriginal":false,"marketingStatus":"BLA"}],"competitors":[{"drugName":"filgrastim","drugSlug":"filgrastim","fdaApproval":"1991-02-20","relationship":"same-class"},{"drugName":"sargramostim","drugSlug":"sargramostim","fdaApproval":"1991-03-05","relationship":"same-class"}],"genericName":"pegfilgrastim","indications":{"approved":[{"name":"Allogeneic peripheral blood stem cell transplant","source":"DrugCentral","snomedId":425843001,"regulator":"FDA","eligibility":null},{"name":"Chemotherapy-induced neutropenia","source":"DrugCentral","snomedId":425229001,"regulator":"FDA","eligibility":null}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"filgrastim","brandName":"filgrastim","genericName":"filgrastim","approvalYear":"1991","relationship":"same-class"},{"drugId":"sargramostim","brandName":"sargramostim","genericName":"sargramostim","approvalYear":"1991","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04685616","phase":"PHASE3","title":"Brentuximab Vedotin in Early Stage Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University College, London","startDate":"2022-04-14","conditions":["Hodgkin Lymphoma"],"enrollment":1042,"completionDate":"2032-09"},{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":["Primary Mediastinal Large B-Cell Lymphoma"],"enrollment":244,"completionDate":"2026-12-31"},{"nctId":"NCT04628767","phase":"PHASE2,PHASE3","title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-11-12","conditions":["Renal Pelvis and Ureter Urothelial Carcinoma"],"enrollment":249,"completionDate":"2027-09-30"},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":["Lymphoproliferative Disorder","HHV-8","Malignancy","HIV"],"enrollment":75,"completionDate":"2026-10-01"},{"nctId":"NCT00066443","phase":"PHASE1,PHASE2","title":"Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2003-11-03","conditions":["Breast Cancer"],"enrollment":93,"completionDate":"2014-01-16"},{"nctId":"NCT07224100","phase":"PHASE2","title":"Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-15","conditions":["B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1","Lymphoblastic Lymphoma"],"enrollment":33,"completionDate":"2028-07-31"},{"nctId":"NCT06528691","phase":"PHASE2","title":"Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-04","conditions":["High Grade Glioma","CNS Tumor"],"enrollment":52,"completionDate":"2032-11"},{"nctId":"NCT07021989","phase":"PHASE2","title":"ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Michael Spinner, MD","startDate":"2026-05-01","conditions":["Hodgkin Lymphoma, Adult","Refractory Hodgkin Lymphoma","Classic Hodgkin Lymphoma"],"enrollment":38,"completionDate":"2033-10-31"},{"nctId":"NCT06738368","phase":"PHASE2","title":"Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-01","conditions":["B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","T Acute Lymphoblastic Leukemia"],"enrollment":30,"completionDate":"2028-07-30"},{"nctId":"NCT03214562","phase":"PHASE1,PHASE2","title":"Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-09-26","conditions":["High Risk Myelodysplastic Syndrome","Recurrent Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia"],"enrollment":116,"completionDate":"2027-09-30"},{"nctId":"NCT03609216","phase":"PHASE2","title":"Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2018-12-10","conditions":["Infiltrating Bladder Urothelial Carcinoma","Stage II Bladder Urothelial Carcinoma","Stage III Bladder Urothelial Carcinoma"],"enrollment":271,"completionDate":"2029-02-01"},{"nctId":"NCT06048484","phase":"PHASE2","title":"Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Gulam Manji","startDate":"2024-05-10","conditions":["Pancreatic Ductal Adenocarcinoma"],"enrollment":60,"completionDate":"2027-04"},{"nctId":"NCT04684368","phase":"PHASE2","title":"A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2021-07-13","conditions":["Central Nervous System Nongerminomatous Germ Cell Tumor","Choriocarcinoma","Embryonal Carcinoma","Immature Teratoma","Malignant Teratoma","Mixed Germ Cell Tumor","Pineal Region Germ Cell Tumor","Pineal Region Immature Teratoma","Pineal Region Yolk Sac Tumor","Suprasellar Germ Cell Tumor"],"enrollment":160,"completionDate":"2029-12-21"},{"nctId":"NCT07192770","phase":"","title":"G-CSF-Induced Bone Pain and Supportive Care Approaches","status":"COMPLETED","sponsor":"Ankara Etlik City Hospital","startDate":"2025-09-27","conditions":["Solid Tumors","Chemotherapy-induced Neutropenia"],"enrollment":225,"completionDate":"2026-02-19"},{"nctId":"NCT05296317","phase":"NA","title":"Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration","status":"COMPLETED","sponsor":"Centre Georges Francois Leclerc","startDate":"2022-09-02","conditions":["Localized Breast Cancer"],"enrollment":97,"completionDate":"2025-09-26"},{"nctId":"NCT07419295","phase":"PHASE3","title":"A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)","status":"NOT_YET_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-17","conditions":["Bladder Cancer"],"enrollment":590,"completionDate":"2030-04-23"},{"nctId":"NCT06709495","phase":"PHASE1,PHASE2","title":"Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas","status":"RECRUITING","sponsor":"David S Shulman, MD","startDate":"2025-01-27","conditions":["Sarcoma","Sarcoma, Ewing","Desmoplastic Small Round Cell Tumor","Refractory Sarcoma","Osteosarcoma","Rhabdomyosarcoma"],"enrollment":63,"completionDate":"2029-09-01"},{"nctId":"NCT07416955","phase":"PHASE1","title":"Pharmacokinetic, Immunogenicity, and Safety Evaluation of Pegfilgrastim TPI-120 in Healthy Adults","status":"COMPLETED","sponsor":"Kashiv BioSciences, LLC","startDate":"2025-04-05","conditions":["Healthy Volunteer"],"enrollment":180,"completionDate":"2025-10-10"},{"nctId":"NCT03136146","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-09","conditions":["Recurrent Acute Lymphoblastic Leukemia","Recurrent Adult Lymphoblastic Lymphoma","Recurrent Burkitt Leukemia","Recurrent Burkitt Lymphoma","Recurrent Childhood Lymphoblastic Lymphoma","Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Refractory Acute Lymphoblastic Leukemia","Refractory Burkitt Leukemia","Refractory Burkitt Lymphoma","Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Refractory Lymphoblastic Lymphoma"],"enrollment":42,"completionDate":"2027-08-01"},{"nctId":"NCT03147612","phase":"PHASE2","title":"Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-02-08","conditions":["Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia With BCR-ABL1","Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Recurrent Acute Lymphoblastic Leukemia","Refractory Acute Lymphoblastic Leukemia"],"enrollment":22,"completionDate":"2027-02-28"},{"nctId":"NCT03301350","phase":"PHASE2","title":"Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2017-11-07","conditions":["Breast Cancer","Triple Negative Breast Cancer"],"enrollment":29,"completionDate":"2022-02-07"},{"nctId":"NCT05535166","phase":"PHASE2","title":"Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-12-20","conditions":["Medulloblastoma"],"enrollment":130,"completionDate":"2035-07"},{"nctId":"NCT05753618","phase":"PHASE4","title":"Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2023-04-17","conditions":["Early-stage Breast Cancer"],"enrollment":242,"completionDate":"2026-10"},{"nctId":"NCT07125183","phase":"PHASE2","title":"Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-12","conditions":["Sarcoma"],"enrollment":20,"completionDate":"2029-12"},{"nctId":"NCT04872543","phase":"PHASE2","title":"A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-04-29","conditions":["Malignant Peripheral Nerve Sheath Tumors (MPNST)"],"enrollment":25,"completionDate":"2027-04"},{"nctId":"NCT06594939","phase":"PHASE2","title":"Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-03","conditions":["Diffuse Large B Cell Lymphoma (DLBCL)"],"enrollment":31,"completionDate":"2029-12"},{"nctId":"NCT04323956","phase":"PHASE1","title":"Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-06-15","conditions":["Ann Arbor Stage II Diffuse Large B-Cell Lymphoma","Ann Arbor Stage II Follicular Lymphoma","Ann Arbor Stage II Marginal Zone Lymphoma","Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","Ann Arbor Stage III Follicular Lymphoma","Ann Arbor Stage III Marginal Zone Lymphoma","Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","Ann Arbor Stage IV Follicular Lymphoma","Ann Arbor Stage IV Marginal Zone Lymphoma","Diffuse Large B-Cell Lymphoma","High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","Indolent Non-Hodgkin Lymphoma"],"enrollment":50,"completionDate":"2028-05-16"},{"nctId":"NCT03943901","phase":"PHASE2","title":"Split-Dose R-CHOP for Older Adults With DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-02-17","conditions":["Diffuse Large B Cell Lymphoma","DLBCL","Cancer"],"enrollment":27,"completionDate":"2027-02"},{"nctId":"NCT05634369","phase":"PHASE1,PHASE2","title":"A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2022-11-14","conditions":["Pediatric Sarcoma, Refractory","Pediatric Sarcoma, Relapsed"],"enrollment":50,"completionDate":"2027-12-01"},{"nctId":"NCT04294641","phase":"PHASE2","title":"Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-10","conditions":["Chronic GVHD"],"enrollment":10,"completionDate":"2024-10-01"},{"nctId":"NCT02586831","phase":"PHASE1,PHASE2","title":"Diabetes Islet Preservation Immune Treatment","status":"WITHDRAWN","sponsor":"Camillo Ricordi and Jay Skyler","startDate":"2024-06-01","conditions":["Diabetes Mellitus, Type 1","Hypoglycemia","Autoimmune Diseases","Diabetes Mellitus"],"enrollment":0,"completionDate":"2024-06-01"},{"nctId":"NCT07059611","phase":"PHASE2","title":"Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2026-04-01","conditions":["Gastric Adenocarcinoma","Esophageal Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma"],"enrollment":34,"completionDate":"2029-11-01"},{"nctId":"NCT04174742","phase":"","title":"Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2019-12-17","conditions":["Breast","Breast Cancer"],"enrollment":102,"completionDate":"2041-01"},{"nctId":"NCT05211336","phase":"PHASE1","title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-04-19","conditions":["Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)","Aggressive B-cell Lymphoma With Secondary Involvement of the CNS"],"enrollment":14,"completionDate":"2029-06-01"},{"nctId":"NCT06220032","phase":"PHASE3","title":"Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma","status":"RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2024-08-15","conditions":["DLBCL - Diffuse Large B Cell Lymphoma"],"enrollment":324,"completionDate":"2028-12-15"},{"nctId":"NCT06414889","phase":"PHASE1","title":"Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-05-20","conditions":["RUNX1 Familial Platelet Disorder"],"enrollment":4,"completionDate":"2027-06-30"},{"nctId":"NCT05130827","phase":"PHASE2","title":"Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-12-21","conditions":["Multiple Myeloma"],"enrollment":17,"completionDate":"2026-11"},{"nctId":"NCT06690775","phase":"PHASE2","title":"CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.","status":"RECRUITING","sponsor":"TORL Biotherapeutics, LLC","startDate":"2024-11-20","conditions":["Epithelial Ovarian Cancer","Primary Peritoneal","Fallopian Tube Cancer","Endometrioid Ovarian Cancer"],"enrollment":230,"completionDate":"2027-12"},{"nctId":"NCT01850888","phase":"NA","title":"MIBG for Refractory Neuroblastoma and Pheochromocytoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2013-12","conditions":["Relapsed Neuroblastoma","Metastatic Pheochromocytoma"],"enrollment":15,"completionDate":"2025-10-20"},{"nctId":"NCT01871766","phase":"PHASE2","title":"Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-04","conditions":["Rhabdomyosarcoma"],"enrollment":115,"completionDate":"2030-06"},{"nctId":"NCT07278856","phase":"PHASE1","title":"Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-04-27","conditions":["Follicular Helper T-Cell Lymphoma","Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type","Follicular Helper T-Cell Lymphoma, Follicular-Type","Follicular Helper T-Cell Lymphoma, Not Otherwise Specified","Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","Peripheral T-Cell Lymphoma, Not Otherwise Specified"],"enrollment":20,"completionDate":"2027-03-31"},{"nctId":"NCT01046825","phase":"PHASE2,PHASE3","title":"Mature B-Cell Lymphoma And Leukemia Study III","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2010-09-09","conditions":["Mature B-Cell Lymphoma"],"enrollment":128,"completionDate":"2027-08"},{"nctId":"NCT03907488","phase":"PHASE3","title":"Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-29","conditions":["Ann Arbor Stage III Hodgkin Lymphoma","Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma","Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma","Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma","Ann Arbor Stage IV Hodgkin Lymphoma","Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma","Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma","Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma","Classic Hodgkin Lymphoma","Lymphocyte-Rich Classic Hodgkin Lymphoma"],"enrollment":994,"completionDate":"2026-03-28"},{"nctId":"NCT01840566","phase":"PHASE1","title":"High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-04","conditions":["Non-Hodgkin's Lymphoma"],"enrollment":17,"completionDate":"2026-04"},{"nctId":"NCT07188090","phase":"PHASE2","title":"Mozobil for Autologous Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2025-10-16","conditions":["Multiple Myeloma","Hodgkin Lymphoma","Non-hodgkin Lymphoma"],"enrollment":100,"completionDate":"2028-06"},{"nctId":"NCT03571633","phase":"PHASE2","title":"Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Leon Berard","startDate":"2018-08-06","conditions":["HER2-positive Breast Cancer","Operable Breast Cancer"],"enrollment":90,"completionDate":"2027-09"},{"nctId":"NCT02810743","phase":"PHASE3","title":"Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2017-01-25","conditions":["Breast Cancer"],"enrollment":174,"completionDate":"2033-12-01"},{"nctId":"NCT06711523","phase":"PHASE3","title":"Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kexing Biopharm Co., Ltd.","startDate":"2025-01-09","conditions":["Neutropenia, Chemotherapy-Induced Febrile","Breast Neoplasm Female"],"enrollment":250,"completionDate":"2026-06-30"},{"nctId":"NCT01933932","phase":"PHASE3","title":"Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2013-09-25","conditions":["Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV"],"enrollment":510,"completionDate":"2025-12-31"},{"nctId":"NCT02369458","phase":"PHASE2","title":"Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2015-04-14","conditions":["Squamous Cell Carcinoma of the Head and Neck","Squamous Cell Carcinoma, Head and Neck"],"enrollment":48,"completionDate":"2024-11-01"},{"nctId":"NCT03036488","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-03-07","conditions":["Triple Negative Breast Neoplasms"],"enrollment":1174,"completionDate":"2025-10-14"},{"nctId":"NCT02909036","phase":"PHASE1","title":"Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-09","conditions":["Multiple Myeloma","Amyloidosis"],"enrollment":46,"completionDate":"2026-09"},{"nctId":"NCT01624805","phase":"PHASE2","title":"Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-06-25","conditions":["Aplastic Anemia","de Novo Myelodysplastic Syndrome","Myelodysplastic Syndrome","Previously Treated Myelodysplastic Syndrome"],"enrollment":140,"completionDate":"2026-06-30"},{"nctId":"NCT05645718","phase":"PHASE2","title":"Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-07-14","conditions":["Leukemia"],"enrollment":27,"completionDate":"2029-12-31"},{"nctId":"NCT05870748","phase":"PHASE2,PHASE3","title":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","status":"TERMINATED","sponsor":"Sutro Biopharma, Inc.","startDate":"2023-07-12","conditions":["Ovarian Cancer","Epithelial Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer","Platinum-resistant Ovarian Cancer"],"enrollment":600,"completionDate":"2025-08-26"},{"nctId":"NCT07184021","phase":"PHASE2","title":"Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-09","conditions":["Urinary Bladder Cancer"],"enrollment":30,"completionDate":"2027-09"},{"nctId":"NCT04383743","phase":"PHASE2","title":"Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2020-11-24","conditions":["Stage II Bladder Cancer AJCC v8","Stage IIIA Bladder Cancer AJCC v8","Muscle Invasive Bladder Carcinoma"],"enrollment":17,"completionDate":"2025-03-04"},{"nctId":"NCT03107988","phase":"PHASE1","title":"NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)","status":"COMPLETED","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2017-09-05","conditions":["Neuroblastoma"],"enrollment":65,"completionDate":"2025-01-31"},{"nctId":"NCT00911183","phase":"PHASE2","title":"Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2008-12-02","conditions":["Lymphoma"],"enrollment":67,"completionDate":"2015-01-01"},{"nctId":"NCT03646123","phase":"PHASE2","title":"Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Seagen Inc.","startDate":"2019-01-28","conditions":["Hodgkin Lymphoma"],"enrollment":255,"completionDate":"2024-08-23"},{"nctId":"NCT06616987","phase":"PHASE2","title":"Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Yeon Hee Park","startDate":"2025-07-03","conditions":["Breast Cancer Metastatic"],"enrollment":40,"completionDate":"2027-12-31"},{"nctId":"NCT05573386","phase":"","title":"Comparison of Quality and Quantity of M-PRP Cellular Content Filgrastim vs. Pegfilgrastim","status":"COMPLETED","sponsor":"Andrews Research & Education Foundation","startDate":"2021-08-09","conditions":["Healthy"],"enrollment":15,"completionDate":"2023-10-05"},{"nctId":"NCT05011188","phase":"PHASE1,PHASE2","title":"FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rahul Aggarwal","startDate":"2022-01-19","conditions":["Metastatic Castration-resistant Prostate Cancer","Prostate Cancer"],"enrollment":44,"completionDate":"2027-07-31"},{"nctId":"NCT00334815","phase":"PHASE2","title":"Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-06-15","conditions":["Lung Adenocarcinoma","Lung Adenosquamous Carcinoma","Lung Large Cell Carcinoma","Lung Squamous Cell Carcinoma","Minimally Invasive Lung Adenocarcinoma","Stage IIIA Lung Non-Small Cell Cancer AJCC v7","Stage IIIB Lung Non-Small Cell Cancer AJCC v7"],"enrollment":29,"completionDate":"2026-02-22"},{"nctId":"NCT06023641","phase":"PHASE2","title":"Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-03-13","conditions":["Rhabdomyosarcoma"],"enrollment":135,"completionDate":"2037-10"},{"nctId":"NCT05032183","phase":"PHASE1,PHASE2","title":"Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-02-17","conditions":["Recurrent Adult Lymphoblastic Lymphoma","Recurrent B Acute Lymphoblastic Leukemia","Recurrent T Acute Lymphoblastic Leukemia","Refractory B Acute Lymphoblastic Leukemia","Refractory Lymphoblastic Lymphoma","Refractory T Acute Lymphoblastic Leukemia"],"enrollment":4,"completionDate":"2024-07-31"},{"nctId":"NCT00049595","phase":"PHASE3","title":"Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2002-08","conditions":["Lymphoma"],"enrollment":552,"completionDate":""},{"nctId":"NCT00070564","phase":"PHASE3","title":"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2003-11","conditions":["Breast Cancer"],"enrollment":3294,"completionDate":"2027-01"},{"nctId":"NCT03220022","phase":"PHASE1","title":"Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-03-16","conditions":["AIDS-Related Lymphoma","Ann Arbor Stage II Diffuse Large B-Cell Lymphoma","Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma"],"enrollment":46,"completionDate":"2026-07-16"},{"nctId":"NCT07064018","phase":"PHASE1,PHASE2","title":"Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-04-30","conditions":["Soft-tissue Sarcoma","Triple Negative Breast Cancer","Non-small Cell Lung Cancer","Cervical Cancer","Ovarian Cancer","KRAS Mutation-Related Tumors"],"enrollment":67,"completionDate":"2031-12-31"},{"nctId":"NCT00812669","phase":"PHASE2","title":"CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2008-08-18","conditions":["Leukemia"],"enrollment":52,"completionDate":"2019-11-21"},{"nctId":"NCT04506554","phase":"PHASE2","title":"A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2020-12-01","conditions":["Muscle-Invasive Bladder Carcinoma"],"enrollment":81,"completionDate":"2028-11"},{"nctId":"NCT06698861","phase":"PHASE1","title":"A Phase I PK/PD Study of PEG-MetHuG-CSF (P2203) in Healthy Volunteers","status":"COMPLETED","sponsor":"PharmaEssentia","startDate":"2024-08-19","conditions":["PK in Healthy Volunteers"],"enrollment":30,"completionDate":"2025-02-06"},{"nctId":"NCT02582697","phase":"PHASE3","title":"Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours","status":"RECRUITING","sponsor":"University of Sydney","startDate":"2014-02","conditions":["Germ Cell Tumor"],"enrollment":500,"completionDate":"2029-12-31"},{"nctId":"NCT01437488","phase":"PHASE2","title":"Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2012-02-16","conditions":["Urothelial Carcinoma"],"enrollment":14,"completionDate":"2017-03-30"},{"nctId":"NCT06918587","phase":"PHASE1","title":"Open Label Randomized Comparative Crossover Pharmacokinetic and Immunogenicity Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kashiv BioSciences, LLC","startDate":"2024-09-05","conditions":["Febrile Neutropenia"],"enrollment":180,"completionDate":"2025-04"},{"nctId":"NCT04781959","phase":"PHASE4","title":"A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2021-06-09","conditions":["Early-stage Breast Cancer"],"enrollment":233,"completionDate":"2023-09-28"},{"nctId":"NCT04023669","phase":"PHASE1","title":"Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-08-08","conditions":["Brain Tumor","Brain Tumor, Recurrent","Brain Tumor, Refractory","Brain Tumor, Pediatric","Medulloblastoma","Medulloblastoma Recurrent","Medulloblastoma, Non-WNT/Non-SHH","Medulloblastoma, Non-WNT/Non-SHH, Group 3","Medulloblastoma, Non-WNT/Non-SHH, Group 4","Brain Cancer","CNS Cancer","CNS Tumor","CNS Neoplasm"],"enrollment":21,"completionDate":"2025-01-13"},{"nctId":"NCT00670358","phase":"PHASE1,PHASE2","title":"Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2008-08-25","conditions":["Lymphoma"],"enrollment":138,"completionDate":"2024-10-04"},{"nctId":"NCT05910164","phase":"","title":"Patient Preference Between a Prefilled Syringe or a Prefilled Pen Device for Administration of Pegfilgrastim","status":"COMPLETED","sponsor":"Institut Rafael","startDate":"2023-06-09","conditions":["Patient Preference","Febrile Neutropenia, Drug-Induced","Patient Satisfaction"],"enrollment":150,"completionDate":"2024-10-09"},{"nctId":"NCT03649438","phase":"","title":"131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma","status":"NO_LONGER_AVAILABLE","sponsor":"University of Texas Southwestern Medical Center","startDate":"","conditions":["Relapsed Neuroblastoma","Metastatic Pheochromocytoma"],"enrollment":0,"completionDate":""},{"nctId":"NCT06094140","phase":"PHASE2","title":"NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2022-05-20","conditions":["Pancreatic Cancer"],"enrollment":20,"completionDate":"2026-06"},{"nctId":"NCT02938442","phase":"PHASE1,PHASE2","title":"Vaccination of Triple Negative Breast Cancer Patients","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2019-01-25","conditions":["Triple Negative Breast Cancer","Breast Neoplasms"],"enrollment":16,"completionDate":"2023-01-09"},{"nctId":"NCT03885284","phase":"PHASE1","title":"Study of Proton Therapy in Adjuvant Pancreatic Cancer","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2019-07-15","conditions":["Resected Pancreatic Adenocarcinoma"],"enrollment":9,"completionDate":"2023-11-08"},{"nctId":"NCT05841186","phase":"NA","title":"Correlation of Timing of Pegfilgrastim Administration and PIBP.","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2023-05-04","conditions":["Pegfilgrastim","Bone Pain","Chemotherapy","Breast Cancer","Patient-reported Outcomes","Quality of Life"],"enrollment":156,"completionDate":"2025-05-31"},{"nctId":"NCT03102606","phase":"PHASE3","title":"Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3","status":"COMPLETED","sponsor":"BeyondSpring Pharmaceuticals Inc.","startDate":"2018-05-29","conditions":["Chemotherapy-induced Neutropenia"],"enrollment":105,"completionDate":"2021-02-08"},{"nctId":"NCT04873765","phase":"PHASE1","title":"Biosimilarity Study of Subcutaneous Pegfilgrastim in Healthy Volunteers","status":"COMPLETED","sponsor":"Megalabs","startDate":"2022-03-18","conditions":["Neutropenia"],"enrollment":72,"completionDate":"2022-09-18"},{"nctId":"NCT05194579","phase":"PHASE1","title":"Pharmacokinetic Comparability Study in Healthy Participants - PF-06881894 On-Body Injector Relative to Prefilled Syringe","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-02-10","conditions":["Healthy Volunteers"],"enrollment":141,"completionDate":"2022-08-10"},{"nctId":"NCT06520176","phase":"PHASE3","title":"Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08","conditions":["Multiple Myeloma","Hematopoietic Stem Cell Mobilization"],"enrollment":99,"completionDate":"2026-12"},{"nctId":"NCT01782339","phase":"PHASE2","title":"A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis","status":"COMPLETED","sponsor":"Barts & The London NHS Trust","startDate":"2012-05-01","conditions":["Germ Cell Tumour"],"enrollment":45,"completionDate":"2021-05-05"},{"nctId":"NCT02073097","phase":"PHASE1,PHASE2","title":"Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2015-01-28","conditions":["Contiguous Stage II Adult Diffuse Large Cell Lymphoma","Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma","Stage I Adult Diffuse Large Cell Lymphoma","Stage III Adult Diffuse Large Cell Lymphoma","Stage IV Adult Diffuse Large Cell Lymphoma"],"enrollment":48,"completionDate":"2023-06-29"},{"nctId":"NCT04345900","phase":"PHASE2","title":"Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2","status":"COMPLETED","sponsor":"BeyondSpring Pharmaceuticals Inc.","startDate":"2017-04-05","conditions":["Chemotherapy-induced Neutropenia"],"enrollment":55,"completionDate":"2018-04-20"},{"nctId":"NCT05043649","phase":"PHASE1","title":"Camsirubicin + Pegfilgrastim to Determine MTD in ASTS","status":"TERMINATED","sponsor":"Monopar Therapeutics","startDate":"2021-09-22","conditions":["Advanced Soft-tissue Sarcoma"],"enrollment":14,"completionDate":"2024-05-13"},{"nctId":"NCT03433560","phase":"","title":"An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta®)","status":"COMPLETED","sponsor":"Kyowa Kirin Korea Co., Ltd.","startDate":"2018-01-18","conditions":["Breast Cancer Female","Breast Neoplasm Female"],"enrollment":1300,"completionDate":"2021-06-30"},{"nctId":"NCT00678327","phase":"PHASE3","title":"Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University College, London","startDate":"2008-08-29","conditions":["Lymphoma"],"enrollment":1202,"completionDate":"2024-05-01"},{"nctId":"NCT00433420","phase":"PHASE3","title":"Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy","startDate":"2003-04","conditions":["Breast Cancer"],"enrollment":2000,"completionDate":"2025-12"},{"nctId":"NCT01783535","phase":"PHASE2","title":"Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-06-19","conditions":["Retinoblastoma"],"enrollment":174,"completionDate":"2028-01"},{"nctId":"NCT03639948","phase":"PHASE2","title":"Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2018-09-04","conditions":["Triple-negative Breast Cancer"],"enrollment":120,"completionDate":"2024-11"},{"nctId":"NCT00837265","phase":"PHASE2,PHASE3","title":"Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2008-08-21","conditions":["Chemotherapy-induced Neutropenia"],"enrollment":334,"completionDate":"2009-06-26"},{"nctId":"NCT05283616","phase":"PHASE3","title":"Reduced Dose of Pegfilgrastim as Support for Chemotherapy for Breast Cancer","status":"COMPLETED","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2017-05-15","conditions":["Neutropenia"],"enrollment":122,"completionDate":"2021-10-15"}],"_emaApprovals":[{"date":"2002-08-22","status":"Authorised","company":"Amgen Europe B.V."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Subcutaneous","formulation":"Injection","formulations":[{"form":"INJECTION","route":"SUBCUTANEOUS","productName":"FYLNETRA"},{"form":"INJECTION","route":"SUBCUTANEOUS","productName":"Fulphila"},{"form":"INJECTION","route":"SUBCUTANEOUS","productName":"Neulasta"},{"form":"INJECTION","route":"SUBCUTANEOUS","productName":"ZIEXTENZO"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"NYVEPRIA"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"STIMUFEND"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"UDENYCA"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000148730","MMSL":"16343","NDDF":"009564","UNII":"3A58010674","VUID":"4021293","VANDF":"4021293","INN_ID":"8114","RXNORM":"2048018","UMLSCUI":"C1136535","chemblId":"CHEMBL1201568","ChEMBL_ID":"CHEMBL1201568","KEGG_DRUG":"D06889","DRUGBANK_ID":"DB00019","PUBCHEM_CID":"70683024","SNOMEDCT_US":"385544005","IUPHAR_LIGAND_ID":"6969","MESH_SUPPLEMENTAL_RECORD_UI":"C455861"},"formularyStatus":[],"originalProduct":{"form":"INJECTION","route":"SUBCUTANEOUS","company":"Amgen Inc","brandName":"Neulasta","isOriginal":true,"marketingStatus":"BLA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2002-","companyName":"Amgen","relationship":"Original Developer"},{"period":"2002","companyName":"Amgen Europe B.V.","relationship":"EMA Licensee"},{"period":"2014","companyName":"Kyowa Hakko Kirin Co., Ltd.","relationship":"PMDA Licensee"}],"publicationCount":1128,"therapeuticAreas":["Hematology"],"_revenueScrapedAt":"2026-04-08 13:58:54.83891+00","atcClassification":{"source":"DrugCentral","atcCode":"L03AA13","allCodes":["L03AA13"]},"biosimilarFilings":[],"originalDeveloper":"Amgen","recentPublications":[],"_revenueClearedDupe":"nyvepria","companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Amgen","companyId":"amgen","modality":"Recombinant protein","firstApprovalDate":"2002","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2002-01-31T00:00:00.000Z","mah":"AMGEN","brand_name_local":null,"application_number":""},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2014-09-26T00:00:00.000Z","mah":"Kyowa Hakko Kirin Co., Ltd.","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-03-21T00:00:00.000Z","mah":"MYLAN GMBH","brand_name_local":null,"application_number":"BLA761075"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-04-16T00:00:00.000Z","mah":"HOSPIRA INC","brand_name_local":null,"application_number":"BLA761111"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-05-26T00:00:00.000Z","mah":"KASHIV BIOSCIENCES LLC","brand_name_local":null,"application_number":"BLA761084"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-08-18T00:00:00.000Z","mah":"AMGEN","brand_name_local":null,"application_number":"BLA125031"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-11-28T00:00:00.000Z","mah":"LUPIN LTD","brand_name_local":null,"application_number":"BLA761212"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:23:42.067162+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}